FORM 10-Q
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                 [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

              For the quarterly period ended     MARCH 31,SEPTEMBER 30, 2009
                                                 ----------------------------------

              [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                  OF THE SECURITIES EXCHANGE ACT OF 1934
                  For the transition period from _____ to -----    -----_____

                         Commission file number 0-10248
                                                ---------------------------------------

                                FONAR CORPORATION
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

                DELAWARE                          11-2464137
   - ---------------------------------------------------------------    ------------------------------------
   (State or other jurisdiction of     (I.R.S. Employer Identification No.)
   incorporation or organization)

110 Marcus Drive     Melville, New York             11747
- ----------------------------------------          ----------
(Address of principal executive offices)          (Zip Code)

                                 (631) 694-2929
               -----------------------------------------------------------------------------------------------------
               Registrant's telephone number, including area code:

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days. YES _X_ NO ___

Indicate by check mark whether the registrant has submitted  electronically  and
posted on its corporate Web site, if any, every  Interactive  Data File required
to be submitted and posted  pursuant to Rule 405 of  Regulation  S-T (232.405 of
this  chapter)  during the  preceding 12 months (or for shorter  period that the
registrant was required to submit and post such files. YES _X_ NO ___

Indicate by check mark whether the registrant is a large  accelerated  filer, an
accelerated  filer, or a  non-accelerated  filer.  See definition of accelerated
filer and large accelerated filer in Rule 12b-2 of the Exchange Act.  (Check(Check one):
Large accelerated  filer ___   Accelerated filer ___   Non-accelerated filer ___
Smaller reporting company _X_

Indicate by check mark whether the  registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes ___ No _X_

Indicate by check mark whether the registrant has submitted  electronically  and
posted on its corporate Website, if any, every Interactive Data File required to
be  submitted  and  posted  pursuant  to Rule 405 of  Regulation  S-T during the
preceding 12 months (or for such shorter period that the registrant was required
to submit and post such files): Yes ___ No ___

Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the close of the latest practicable date.

                Class                        Outstanding at April 30,October 31, 2009
- -----------------------------------------    ------------------------------------------------------------
Common Stock, par value $.0001                          4,904,2754,916,275
Class B Common Stock, par value $.0001                        158
Class C Common Stock, par value $.0001                    382,513
Class A Preferred Stock, par value $.0001                 313,451



FONAR CORPORATION AND SUBSIDIARIES INDEX

PART I - FINANCIAL INFORMATION                                       PAGE

Item 1.  Financial Statements

Condensed  Consolidated  Balance  Sheets - March 31,September
  30, 2009 (Unaudited) and June 30, 20082009

Condensed Consolidated  Statements of Operations for
  the  Three  Months  Ended  March 31,September  30,  2009  and
  March 31, 2008 (Unaudited)

   Condensed Consolidated Statements of Operations for
     the Nine Months Ended March 31, 2009 and
     March 31,September 30, 2008 (Unaudited)

Condensed  Consolidated  Statements of Comprehensive
  Income (Loss)Loss for the Three Months Ended  March 31,September  30, 2009
  and March 31, 2008 (Unaudited)

   Condensed Consolidated Statements of Comprehensive
     Income (Loss) for the Nine Months Ended
     March 31, 2009 and March 31,September 30, 2008 (Unaudited)

Condensed Consolidated Statements of Cash Flows for
  the NineThree Months Ended March 31,September 30, 2009 and
  March 31,September 30, 2008 (Unaudited)

   Notes to Condensed Consolidated Financial Statements (Unaudited)

Item 2. Management's Discussion and Analysis of Financial
        Condition and Results of Operations

Item 3. Quantitative and Qualitative Disclosures About
        Market Risk

Item 4. Controls and Procedures

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

Item 2. Changes in Securities

Item 3. Defaults Upon Senior Securities

Item 4. Submission of Matters to a Vote of Security Holders

Item 5. Other Information

Item 6. Exhibits

Signatures


                       FONAR CORPORATION AND SUBSIDIARIES
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                                 (000's OMITTED)

ASSETS                                              March 31,September 30,    June 30,
                                                        2009           20082009
                                                     (UNAUDITED)
Current Assets:                                     ----------  -----------------------  -------------
  Cash and cash equivalents                          $     1,6051,372    $     1,3261,226

  Marketable securities                                       18       1,06827             23

  Accounts receivable - net                                5,206       4,6895,156          5,392

  Accounts receivable - related parties - net                619         469179           -

  Medical receivables - net                                  555       1,228316            374

  Management fee receivable  - net                           4,051       5,0403,304          3,274

  Management fee receivable - related
    medical practices - net                                1,480       1,3722,020          2,196

  Costs and estimated earnings in excess
    of billings on uncompleted contracts                   528           61,212          1,476

  Inventories                                              3,793       3,2563,452          3,172

  Current portion of advances and notes to related
    medical practices                                        193         214166            165

  Current portion of notes receivable                      less discount
    for below market interest                                   509       2,5081,664            518

  Prepaid expenses and other current assets                  409         811
                                                         ----------  ----------345            472
                                                    -------------  -------------
        Total Current Assets                              18,966      21,987
                                                         ----------  ----------19,213         18,288
                                                    -------------  -------------

Property and equipment - net                               3,152       3,9332,696          2,892

Advances and notes to related medical practices - net         133         26345             89

Notes receivable  less discount for below market interest      1,912       2,297net                                        156          1,779

Other intangible assets - net                              4,896       4,8104,951          4,920

Other assets                                                 574       1,936
                                                         ----------  ----------391            391
                                                    -------------  -------------
        Total Assets                                 $    29,63327,452    $    35,226
                                                         ==========  ==========28,359
                                                    =============  =============


See accompanying notes to condensed consolidated financial statements
(unaudited).



                       FONAR CORPORATION AND SUBSIDIARIES
                     CONDENSED CONSOLIDATED BALANCE SHEETS
                                (000's OMITTED)

                                                    March 31,September 30,    June 30,
LIABILITIES AND STOCKHOLDERS' DEFICIENCY                 2009          20082009
                                                      (UNAUDITED)
Current Liabilities:                                ----------  -----------------------  -------------
  Current portion of long-term debt and
    capital leases                                   $       141267    $       373277
  Current portion of long-term debt-related party             82             80
  Accounts payable                                         3,720       4,0203,816          3,519
  Other current liabilities                                8,045       8,3168,429          8,460
  Unearned revenue on service contracts                    5,045       4,7325,423          5,526
  Unearned revenue on service
    contracts - related parties                              612         462165           -
  Customer advances                                        7,871      12,804
  Customer advances - related party                             854       1,4729,264          9,238
  Billings in excess of costs and estimated
    earnings on uncompleted contracts                      5,133       5,773
                                                         ----------  ----------2,536          2,026
                                                    -------------  -------------
      Total Current Liabilities                           31,421      37,95229,982         29,126

Long-Term Liabilities:
  Accounts payable                                           156            184
  Due to related medical practices                           95          98658            643
  Long-term debt and capital leases,
   less current portion                                      746         757731            759
  Long-term debt less current portion-related party          139            160
  Other liabilities                                          319         497
                                                         ----------  ----------379            364
                                                    -------------  -------------
      Total Long-Term Liabilities                          1,160       1,352
                                                         ----------  ----------2,063          2,110
                                                    -------------  -------------
      Total Liabilities                                   32,581      39,304
                                                         ----------  ----------32,045         31,236
                                                    -------------  -------------
Minority interest                                             64             167
                                                         ----------  ----------64
                                                    -------------  -------------


See accompanying notes to condensed consolidated financial statements
(unaudited).



                       FONAR CORPORATION AND SUBSIDIARIES
                     CONDENSED CONSOLIDATED BALANCE SHEETS
                       (000's OMITTED, except share data)

                                                    March 31,September 30,    June 30,
LIABILITIES AND STOCKHOLDERS' DEFICIENCY                2009           20082009
     (continued)                                      (UNAUDITED)
                                                    ----------  -----------------------  -------------
STOCKHOLDERS' DEFICIENCY:

Class A non-voting preferred stock $.0001 par
value; 1,600,000 authorized, 313,451 issued and
outstanding at March 31,September 30, 2009 and June 30, 20082009         -              -

Preferred stock $.001 par value; 2,000,000 shares
authorized, issued and outstanding       none               -              -

Common Stock $.0001 par value; 30,000,000 shares
authorized at March 31,September 30, 2009 and June 30, 2008,
4,915,9182009,
4,927,918 and 4,917,918 issued at March 31,September 30, 2009
and June 30, 2008
4,904,2752009, respectively; 4,916,275 and
4,906,275 outstanding at March 31,September 30, 2009 and
June 30, 20082009, respectively                                    1              1

Class B Common Stock $ .0001$.0001 par value; 800,000
shares authorized, (10 votes per share), 158
issued and outstanding at March 31,September 30, 2009 and
June 30, 20082009                                               -               -

Class C Common Stock $.0001 par value; 2,000,000
shares authorized, (25 votes per share), 382,513
issued and outstanding at March 31,September 30, 2009 and
June 30, 20082009                                               -              -

Paid-in capital in excess of par value                   172,276     172,276172,299        172,280
Accumulated other comprehensive loss                         (     25)   (     73)(17)           (21)
Accumulated deficit                                     (174,320)   (175,380)(176,000)      (174,259)
Notes receivable from employee stockholders                 (    269)   (    394)(265)          (267)
Treasury stock, at cost - 11,643 shares of common
  stock at March 31,September 30, 2009 and June 30, 2008                      (    675)   (    675)
                                                         ----------  ----------2009             (675)          (675)
                                                    -------------  -------------
    Total Stockholders' Deficiency                        (  3,012)   (  4,245)
                                                         ----------  ----------(4,657)        (2,941)
                                                    -------------  -------------
    Total Liabilities and Stockholders' Deficiency   $    29,63327,452    $    35,226
                                                         ==========  ==========28,359
                                                    =============  =============

See accompanying notes to condensed consolidated financial statements
(unaudited).


                       FONAR CORPORATION AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)
                     (000's OMITTED, except per share data)

                                                     FOR THE THREE MONTHS ENDED
                                                            MARCH 31,
                                                         ----------------------SEPTEMBER 30,
                                                    ----------------------------
                                                        2009           2008
REVENUES                                            ----------  -----------------------  -------------
  Product sales - net                                $     6,1561,563    $     2,3481,413
  Service and repair fees - net                            2,291       2,5152,757          2,545
  Service and repair fees - related parties - net             331         27055             55
  Management and other fees - net                          1,736          2,1102,047
  Management and other fees - related medical
    practices - net                                          742         828
                                                         ----------  ----------795            724
  License fees and royalties                                 585           -
                                                    -------------  -------------
     Total Revenues - Net                                  11,256       8,071
                                                         ----------  ----------7,491          6,784
                                                    -------------  -------------
COSTS AND EXPENSES
  Costs related to product sales                           3,325       2,2371,657          1,442
  Costs related to service and repair fees                   865       1,148941          1,010
  Costs related to service and repair fees -
    related parties                                           125         12319             22
  Costs related to management and other fees               1,039       1,3421,268          1,203
  Costs related to management and other
    fees - related medical practices                         686         751761            656
  Research and development                                   872       1,189854            880
  Selling, general and administrative                      3,219       4,3113,233          3,265
  Provision (Credit) for bad debts                                    363     (   309)
                                                         ----------  ----------180            154
                                                    -------------  -------------
     Total Costs and Expenses                              10,494      10,792
                                                         ----------  ----------
Income (Loss)8,913          8,632
                                                    -------------  -------------
Loss From Operations                                      762     ( 2,721)(1,422)        (1,848)

Interest Expense                                             (    75)    (   105)(79)           (79)
Interest Expense - Related Party                              (14)           -
Investment Income                                             91         15687             33
Interest Income - Related Parties                                 5           8Party                                4              6
Other (Expense) Income                                                  (    17)33              1
Minority Interest in Income of Partnerships                 -               (    34)
Provision for Income Taxes                                  (    36)       -
                                                         ----------  ----------
NET INCOME (LOSS)                                        $      730  $  ( 2,695)
                                                         ==========  ==========
Net Income (Loss) Available to Common Stockholders       $      686  $   (2,695)
                                                         ==========  ==========
Basic Net Income (Loss) Per Common Share                 $     0.14  $    (0.55)
                                                         ==========  ==========
Diluted Net Income (Loss) Per Common Share               $     0.13  $    (0.55)
                                                         ==========  ==========
Basic and Diluted Income Per Share - Common C            $     0.04        -
                                                         ==========  ==========
Weighted Average Basic Shares Outstanding                 4,904,275   4,904,261
                                                         ==========  ==========
Weighted Average Diluted Shares Outstanding               5,031,779   4,904,261
                                                         ==========  ==========

See accompanying notes to condensed consolidated financial statements
(unaudited).


FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(000's OMITTED, except per share data)
                                                       FOR THE NINE MONTHS ENDED
                                                               MARCH 31,
                                                         ----------------------
                                                            2009        2008
REVENUES                                                 ----------  ----------
  Product sales - net                                    $   11,975  $    8,940
  Service and repair fees - net                               6,936       7,444
  Service and repair fees - related parties - net               966         786
  Management and other fees - net                             5,518       6,354
  Management and other fees - related medical
    practices - net                                           2,181       2,739
  License fees and royalties                                  1,755       1,158
                                                         ----------  ----------
     Total Revenues - Net                                    29,331      27,421
                                                         ----------  ----------
COSTS AND EXPENSES
  Costs related to product sales                              7,590       8,566
  Costs related to service and repair fees                    2,696       3,546
  Costs related to service and repair
    fees - related parties                                      376         375
  Costs related to management and other fees                  3,316       3,898
  Costs related to management and other
    fees - related medical practices                          2,040       2,241
  Research and development                                    2,681       3,675
  Selling, general and administrative                         9,955      15,544
  Provision for bad debts                                     1,063         279
                                                         ----------  ----------
     Total Costs and Expenses                                29,717      38,124
                                                         ----------  ----------
Loss From Operations                                        (   386)    (10,703)

Interest Expense                                            (   193)    (   362)
Investment Income                                               236         531
Interest Income - Related Parties                                17          27
Other (Expense) Income                                      (    15)          7
Minority Interest in Income of Partnerships                 (    11)    (   208)
Gain on Sale of Investment                                     -            571(11)
Gain on Sale of Consolidated Subsidiary                     -             1,448
3,395
Provision for Income Taxes                                  (    36)Loss on Note Receivable                                     (350)          -
                                                    ----------  -----------------------  -------------
NET INCOME (LOSS)LOSS                                             $    1,060(1,741)   $      ( 6,742)
                                                         ==========  ==========

Net Income (Loss) Available to Common Stockholders       $      997  $   (6,742)
                                                         ==========  ==========(450)
                                                    =============  =============

Basic Net Income (Loss)and Diluted Loss Per Common Share                  $     0.20  $    (1.38)
                                                         ==========  ==========
Diluted Net Income (Loss) Per Common Share               $     0.19  $    (1.38)
                                                         ==========  ==========
Basic and Diluted Income per share - Common C            $     0.05        -
                                                         ==========  ==========$(0.35)       $(0.09)
                                                    =============  =============
Weighted Average BasicNumber of Common Shares Outstanding   4,907,942      4,904,275
                                                    4,895,907
                                                         ==========  ==========
Weighted Average Diluted Common Shares Outstanding        5,031,779   4,895,907
                                                         ==========  =======================  =============

See accompanying notes to condensed consolidated financial statements
(unaudited).


                       FONAR CORPORATION AND SUBSIDIARIES
             CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)LOSS
                                   (UNAUDITED)
                                (000'S OMITTED)


                                                     FOR THE THREE MONTHS ENDED
                                                           MARCH 31,
                                                         ----------------------SEPTEMBER 30,
                                                    ----------------------------
                                                        2009           2008
                                                    ----------  -----------------------  -------------
Net income (loss)loss                                             $    730(1,741)   $      (2,695)

Other comprehensive (loss) income, net of tax:
    Unrealized (losses) gains on marketable securities,
      net of tax                                             (    1)         12
                                                         ----------  ----------
Total comprehensive income (loss)                        $      729  $   (2,683)
                                                         ==========  ==========

See accompanying notes to condensed consolidated financial statements
(unaudited).


FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(UNAUDITED)
(000'S OMITTED)


                                                       FOR THE NINE MONTHS ENDED
                                                               MARCH 31,
                                                         ----------------------
                                                            2009        2008
                                                         ----------  ----------
Net income (loss)                                        $    1,060  $  ( 6,742)(450)

Other comprehensive income net of tax:
    Unrealized gains on marketable securities,
      net of tax                                               48          20
                                                         ----------  ----------4             55
                                                    -------------  -------------
Total comprehensive income (loss)loss                             $    1,108(1,737)   $    (  6,722)
                                                         ==========  ==========395)
                                                    =============  =============


See accompanying notes to condensed consolidated financial statements
(unaudited).


                       FONAR CORPORATION AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)
                                (000'S OMITTED)


                                                     FOR THE NINETHREE MONTHS ENDED
                                                           MARCH 31,
                                                         ----------------------SEPTEMBER 30,
                                                    ----------------------------
                                                        2009           2008
                                                    ----------  -----------------------  -------------
Cash Flows from Operating Activities:Activities
 Net income (loss)loss                                            $    1,060(1,741)   $      (  6,742)(450)
 Adjustments to reconcile net income (loss)loss to net
  cash used inprovided by (used in) operating activities:
    Minority interest in income of partnerships             -                11         208
    Depreciation and amortization                            1,297       1,727
    Provision for bad debts                                   1,063         279
    Stock issued for costs and expenses                        -            205366            435
    Gain on sale of consolidated subsidiary                 -            (1,448)
    (3,395)
    GainDiscount on salenote receivable                              350           -
    Provision for bad debts                                  180            154
    Compensatory element of investmentstock issuances                   18           -         (  571)
    (Increase) decrease in operating assets, net:
       Accounts, management fee and medical receivable(s)     (1,093)     (3,351)82            198
       Notes receivable                                      385         424126            144
       Costs and estimated earnings in excess of
         billings on uncompleted contracts                   (  522)      -264              6
       Inventories                                          (  537)        788(280)            54
       Prepaid expenses and other current assets             402      (  196)128             56
       Other assets                                         (   17)     (   90)-                (9)
       Advances and notes to related medical practices        151         13943             68
    Increase (decrease) in operating liabilities, net:
       Accounts payable                                      (  284)     (  294)269            234
       Other current liabilities                              192       1,78031           (728)
       Customer advances                                      (5,551)      4,72926         (1,020)
       Billings in excess of costs and estimated
         earnings on uncompleted contracts                   (  641)        113509            345
       Other liabilities                                      (  178)        11416            (36)
       Due to related medical practices                       (    2)       -
                                                         ----------  ----------15             (5)
                                                    -------------  -------------
Net cash used inprovided by (used in) operating activities               (5,712)     (4,133)
                                                         ----------  ----------402         (1,991)
                                                    -------------  -------------

See accompanying notes to condensed consolidated financial statements
(unaudited).


                       FONAR CORPORATION AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)
                                (000'S OMITTED)

                                                     FOR THE NINETHREE MONTHS ENDED
                                                           MARCH 31,
                                                         ----------------------SEPTEMBER 30,
                                                    ----------------------------
                                                        2009           2008
                                                    ----------  -----------------------  -------------
Cash Flows from Investing Activities:
  PurchasesSales of marketable securities                               -          (   765)
  Sales of marketable securities                              1,098       1,7081,099
  Purchases of property and equipment                         (   20)    (   356)(7)            (1)
  Costs of capitalized software development                 (  392)    (   426)(105)          (149)
  Cost of patents                                            (  192)    (   113)(88)           (60)
  Proceeds from note receivable                             2,000        -             Proceeds from cash surrender value of life insurance        1,345        -
  Proceeds from sale of investment                             -            5712,000
  Proceeds from sale of consolidated subsidiary             -             2,293
                                                    4,142
                                                         ----------  -----------------------  -------------
Net cash (used in) provided by investing activities         6,132       4,761
                                                         ----------  ----------(200)         5,182
                                                    -------------  -------------

Cash Flows from Financing Activities:
  Distributions to holders of minority interests             (   23)     (  117)
  Proceeds from long-term debtinterest             -               265(23)
  Repayment of borrowings and capital
    lease obligations                                        (  243)     (  200)(57)          (104)
  Repayment of notes receivable from employee
     stockholders                                              125         128
                                                         ----------  ----------1              1
                                                    -------------  -------------
Net cash (used in) provided byused in financing activities                        (  141)         76
                                                         ----------  ----------(56)          (126)
                                                    -------------  -------------

Net Increase in Cash and Cash Equivalents                    279         704146          3,065

Cash and Cash Equivalents - Beginning of Period            1,226          1,326
                                                    1,470
                                                         ----------  -----------------------  -------------
Cash and Cash Equivalents - End of Period            $     1,6051,372    $     2,174
                                                         ==========  ==========4,391
                                                    =============  =============

See accompanying notes to condensed consolidated financial statements
(unaudited).



                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               MARCH 31,SEPTEMBER 30, 2009
                                  (UNAUDITED)


NOTE 1 - BASIS OF PRESENTATION & LIQUIDITY & CAPITAL RESOURCES

Basis of Presentation
- ---------------------

The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial  information and with the  instructions to Form 10-Q and Article 10 of
Regulation  S-X.  Accordingly,  they do not include all of the  information  and
footnotes  required by accounting  principles  generally  accepted in the United
States  of  America  for  complete  financial  statements.  In  the  opinion  of
management, all adjustments (consisting of normal recurring accruals) considered
necessary for a fair presentation have been included.  Operating results for the
three and nine months ended  March 31,September  30, 2009 are not  necessarily  indicative  of the
results  that may be expected  for the fiscal year  ending  June 30,  2009.2010.  For
further  information,   refer  to  the  consolidated  financial  statements  and
footnotes  thereto included in the Company's Annual Report on Form 10-K filed on
October 7, 20085, 2009 for the fiscal year ended June 30, 2008.2009.

Liquidity and Capital ResourcesGoing Concern
- -------------------------------

In---------------------------

At  September  2008,  the Company sold its 92.3% interest (to a related party) in
an entity that provided management services to a scanning center in Bensonhurst,
New York and received net cash proceeds of approximately $2.3 million.

In August 2008, the Company signed a modification  agreement with regards to the
asset purchase  agreement  with Health Plus.  The Company  received a $2,000,000
payment on the note issued by Health Plus.

At March 31,30,  2009,  the  Company  had  a  working   capital   deficit  of
approximately $12.5$10.8 million and a stockholders'stockholders  deficiency of approximately $3.0$4.7
million.  For the ninethree months ended March 31,September 30, 2009, the Company  generatedincurred a
net incomeloss of  approximately  $1.1$1.7 million,  which  was due  mainly to the  improvement  in the
Company's  operations and a gainincluded  non-cash  charges of
$1.4 million from the sale of a consolidated
subsidiary.approximately  $914,000.  The Company  has funded its cash flow  deficit for the
ninethree months ended March 31,September 30, 2009 through cash provided by the sale of marketable  securities
and other assets  discussed  above.  In addition,  during June 2008, theoperations.

The Company
implemented a  restructuring  program,  including a reduction of its  workforce,
across the board salary reductions,  elimination of manufacturing facilities and
restructuring of its diagnostic imaging management service business.  Management
estimates that the annualized  savings  related to these  cost-cutting  measures
approximates $5,000,000.

Although  sales  levels  remained  weak in fiscal  2009,  the  Company  has been
profitable  for two  consecutive  quarters and continues to focus its efforts on increased  advertising and marketing  campaigns  and  distribution  programs to
strengthen the demand for its products and services. Management anticipates that
its capital  resources  will improve if Fonar'sFonars MRI scanner  products  gain wider
market recognition and acceptance  resulting in increased product sales. If the
Company is not successful with its marketing  efforts to increase sales and weak
demand continues,  the Company will experience a shortfall in cash over the next
twelve months. If necessary,  the Company will implement its plan to fund such a
deficit  which  includes  further  reductions  in operating  expenses,  sales of
certain assets and loans from related parties  together in an amount  sufficient
to continue as a going concern through March 31, 2010. Current
economic credit  conditions have contributed to a slowing business  environment.
Given such liquidity and credit constraints in the markets, the business has and
may  continue  to  suffer,  should the credit  markets  not  improve in the near
future. The direct impact of these conditions is not fully known. However, there
can be no assurance that the Company would be able to secure additional funds if
needed and that if such funds were  available,  whether the terms or  conditions
would be  acceptable  to the  Company.  In such case,  the further  reduction in
operating  expenses as well as  possible  sale of other  operating  subsidiaries
might need to be substantial in order for the Company to generate  positive cash
flow to sustain the operations of the Company.

The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance  with  accounting  principles  generally  accepted in the
United States of America (USGAAP) and assume that the Company will continue as a
going  concern.  These  conditions  raise  substantial  doubt about the Companys
ability to continue as a going concern.  The  accompanying  unaudited  condensed
consolidated  financial  statements  do not include any  adjustments  that might
result from the outcome of this uncertainty.



                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               MARCH 31,SEPTEMBER 30, 2009
                                  (UNAUDITED)


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation
- ---------------------------

The unaudited condensed  consolidated  financial statements include the accounts
of  FONAR   Corporation,   its  majority  and   wholly-owned   subsidiaries  and
partnerships  (collectively the "Company")Company). All significant  intercompany accounts
and transactions have been eliminated in consolidation.

Earnings (Loss) Per Share
- -------------------------

Basic  earnings  (loss) per share  ("EPS")(EPS) is computed  based on weighted  average
shares outstanding and excludes any potential  dilution.  In accordance with EITF
03-6,  "ParticipatingASC
topic 260 (EITF 03-6),  Participating  Securities and the Two-Class method under
FASB Statement No. 128" ("EITF  03-6"),128, the Company'sCompanys participating convertible securities, which
include Class A Non-voting preferred stock, Class B common stock and Class C common  stock,  are not included in the
computation of basic EPS for the nine
months  and  three months ended March 31,September 30, 2009 and 2008,
because the  participating  securities do not have a  contractual  obligation to
share in the losses of the Company.  For the nine months and three months ended March 31, 2009, the Company
used the Two-Class  method for calculating  basic earnings per share and applied
the if converted method in calculating diluted earnings per share.

Diluted EPS reflects the  potential  dilution from the exercise or conversion of
all dilutive  securities  into common stock based on the average market price of
common  shares  outstanding  during  the  period.  The  number of common  shares
potentially  issuable  upon the  exercise  of certain  options  and  warrants or
conversion of the participating  convertible  securities that were excluded from
the diluted EPS calculation was  approximately  278,000224,000 and 267,000 because they
were  antidilutive  as a result of net losses for the three month  periods ended
September 30, 2009 and nine months ended March
31,  2008.  For the three and nine months  ended March 31,  2009,  the number of
common  shares  potentially  issuable  upon the  exercise of certain  options of
138,000  have not been  included  in the  computation  of diluted  EPS since the
effect would be antidilutive.


                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                 MARCH 31, 2009
                                   (UNAUDITED)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Earnings (Loss) Per Share (Continued)
- -------------------------------------

                                     Three months ended       Three months ended
                                       March 31, 2009           March 31, 2008, ----------------------------  ------------------
                                      (000's omitted, except per share data)

                                                     Class C
                                           Common    Common
Basic                             Total    Stock     Stock
- ------------------------------  --------  --------  --------
Numerator:
  Net income (loss) available
    to common stockholders      $   686   $   672   $    14       $  (2,695)
                                ========  ========  ========  ==================
Denominator:
  Weighted average
    shares outstanding                      4,904       383           4,904
                                          ========  ========  ==================
Basic income (loss)
  per common share                        $  0.14   $  0.04       $   (0.55)
                                          ========  ========  ==================

Diluted
- ------------------------------
Denominator:
  Weighted average
    shares outstanding            4,904     4,904       383           4,904
  Stock options                    -         -         -               -
  Warrants                         -         -         -               -
  Convertible Class C Stock         128       128      -               -
                                --------  --------  --------  ------------------
  Total Denominator for
    diluted earnings per share    5,032     5,032       383           4,904
                                ========  ========  ========  ==================
Diluted income (loss)
  per common share                        $  0.13   $  0.04       $   (0.55)
                                          ========  ========  ==================


                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                 MARCH 31, 2009
                                   (UNAUDITED)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Earnings (Loss) Per Share (Continued)
- -------------------------------------

                                      Nine months ended       Nine months ended
                                        March 31, 2009          March 31, 2008
                                ----------------------------  -----------------
                                      (000's omitted, except per share data)

                                                     Class C
                                           Common    Common
Basic                             Total    Stock     Stock
- ------------------------------  --------  --------  --------
Numerator:
  Net income (loss) available
    to common stockholders      $   997   $   977   $    20       $  (6,742)
                                ========  ========  ========  =================
Denominator:
  Weighted average
    shares outstanding                      4,904       383           4,896
                                          ========  ========  =================
Basic income (loss)
  per common share                        $  0.20   $  0.05       $   (1.38)
                                          ========  ========  =================

Diluted
- ------------------------------
Denominator:
  Weighted average
    shares outstanding            4,904     4,904       383           4,896
  Stock options                    -         -         -               -
  Warrants                         -         -         -               -
  Convertible Class C Stock         128       128      -               -
                                --------  --------  --------  -----------------
  Total Denominator for
    diluted earnings per share    5,032     5,032       383           4,896
                                ========  ========  ========  =================
Diluted income (loss)
  per common share                        $  0.19   $  0.05       $   (1.38)
                                          ========  ========  =================respectively.

Recent Accounting Pronouncements
- --------------------------------

In September  2006,  the  Financial  Accounting  Standard  Board  ("FASB")(FASB)  issued
Accounting  Standards  Codification  (ASC)  topic  820  (formerly  Statement  of
Financial Accounting  Standards ("SFAS")(SFAS) No. 157, "FairFair Value  Measurements," ("SFAS 157")Measurements).  This
statement  provides a single definition of fair value, a framework for measuring
fair  value,  and  expanded  disclosures  concerning  fair  value.   Previously,
different  definitions  of fair  value  were  contained  in  various  accounting
pronouncements  creating  inconsistencies  in measurement and  disclosures.  SFAS 157ASC
topic 820 applies under those previously  issued  pronouncements  that prescribe
fair value as the relevant measure of value, except SFAS No. 123 (revised 2004),
"Share-Based  Payment",Share-Based Payment, and related interpretations and pronouncements that require
or permit measurement similar to fair value but are not intended to measure fair
value.  The Company  adopted SFAS 157ASC topic 820 on July 1, 2008,  as required for its
financial  assets and  financial  liabilities.  However,  the FASB  deferred the
effective  date of SFAS 157ASC  topic  820 for one  year  as it  relates  to fair  value
measurement  requirements for nonfinancial  assets and nonfinancial  liabilities
that are not  recognized  or disclosed at fair value on a recurring  basis.  The
adoption of SFAS 157the  provisions of ASC topic 820 for the Company'sCompanys  financial  assets
and  financial  liabilities  did not have a  material  impact  on its  condensed
consolidated  financial  statements.  The Company is  evaluating  the effect the
implementation  of SFAS 157ASC topic 820 for its  nonfinancial  assets and  nonfinancial
liabilities  will  have  on  the  Company'sCompanys  condensed   consolidated   financial
statements.



                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               MARCH 31,SEPTEMBER 30, 2009
                                  (UNAUDITED)


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)(Continued)

Recent Accounting Pronouncements (Continued)
- --------------------------------------------

Effective   January  1,  2007,  the  Company  adopted  the  provisions  of  FASB
Interpretation   No.  48,   "Accounting  of   Uncertainty  in  Income   Taxes-an
interpretation  of FASB  Statement  No. 109" ("FIN  48").  FIN 48  prescribes  a
recognition  threshold and  measurement  attribute  for the financial  statement
recognition and measurement of a tax position taken or expected to be taken in a
corporate tax return.  For those benefits to be recognized,  a tax position must
be  more-likely-than-not to be sustained upon examination by taxing authorities.
Differences  between tax positions taken or expected to be taken in a tax return
and the benefit  recognized  and  measured  pursuant to the  interpretation  are
referred to as "unrecognized  benefits". A liability is recognized (or amount of
net operating  loss carry forward or amount of tax refundable is reduced) for an
unrecognized tax benefit because it represents an enterprise's  potential future
obligation to the taxing authority for a tax position that was not recognized as
a result  of  applying  the  provisions  of FIN 48. In  accordance  with FIN 48,
interest  costs  related  to  unrecognized  tax  benefits  are  required  to  be
calculated (if applicable) and would be classified as "Interest  expense,  net".
Penalties  if  incurred  would be  recognized  as a component  of  "General  and
administrative"  expenses. The Company files corporate income tax returns in the
United States  (federal) and in various state and local  jurisdictions.  In most
instances,  the Company is no longer subject to federal,  state and local income
tax examinations by tax authorities for years prior to 2004. The adoption of the
provisions  of  FIN  48  did  not  have  a  material  impact  on  the  Company's
consolidated financial position and results of operations. As of March 31, 2009,
no liability  for  unrecognized  tax  benefits was required to be recorded.  The
Company recognized a deferred tax asset of approximately $76 million as of March
31, 2009, primarily related to net operating loss carryforwards of approximately
$165 million, available to offset future taxable income through 2028.--------------------------------

On February 15,  2007,  the FASB issued ASC topic 820  (formerly  SFAS No. 159,159),
entitled ``The Fair Value Option for Financial  Assets and Financial  Liabilities,''  ("SFAS  159").Liabilities.
The  guidance  in SFAS 159 ``allows''ASC topic 820 allows  reporting  entities to ``choose''choose to measure
many financial  instruments and certain other items at fair value. The objective
underlying the development of this literature is to improve financial  reporting
by providing  reporting  entities with the  opportunity to reduce  volatility in
reported  earnings that results from measuring  related  assets and  liabilities
differently without having to apply complex hedge accounting  provisions,  using
the guidance in SFAS No. 133, as amended,  entitled  ``Accounting  for  Derivative
Instruments  and  Hedging  Activities.''  The  provisions  of SFAS  No.  159ASC  topic  820  are
applicable  to all  reporting  entities and are effective as of the beginning of
the first fiscal year that begins  subsequent to November 15, 2007.  The Company
adopted SFAS 159ASC topic 820 effective July 1, 2008. Upon adoption, the Company did not
elect the fair value option for any items within the scope of SFAS 159ASC topic 820 and,
therefore,  the adoption of SFAS 159ASC topic 820 did not have an impact on the Company'sCompanys
condensed consolidated financial statements.
                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                 MARCH 31, 2009
                                   (UNAUDITED)


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Recent Accounting Pronouncements (Continued)
- --------------------------------------------

In March 2007,  the FASB ratified ASC topic 715  (formerly  the Emerging  Issues
Task Force  ("EITF")(EITF)  consensus on EITF Issue No.  06-10.  "Accounting06-10).  Accounting  for  Collateral
Assignment  Split Dollar Life  Insurance".Insurance.  This EITFASC topic 715 indicates  that an
employer should  recognize a liability for  postretirement  benefits  related to
collateral assignment split-
dollarsplit-dollar life insurance arrangements. In addition, the
EITFASC topic 715 provides  guidance for the  recognition  of an asset  related to a
collateral assignment split-dollar life insurance arrangement. The EITFASC topic 715
is effective for fiscal years beginning after December 15, 2007. The Company has
adopted  the EITFASC  topic  715 as  required  and it did not have an  impact on the
Company'sCompanys results of operations, financial condition and liquidity.

In  December  2007,  the FASB  issued ASC topic 805  (formerly  SFAS No.  141R, "Business  Combinations" ("SFAS
141R")141R),
Business Combinations,  which replaces SFAS No. 141, "Business  Combinations".  SFAS  141RBusiness Combinations.  ASC
topic  805  establishes  principles  and  requirements  for  determining  how an
enterprise  recognizes  and  measures  the fair  value  of  certain  assets  and
liabilities  acquired  in  a  business  combination,   including  noncontrolling
interests,  contingent  consideration,  and certain acquired contingencies.  SFAS 141RASC
topic  805  also   requires   acquisition-related   transaction   expenses   and
restructuring  costs be  expensed  as  incurred  rather  than  capitalized  as a
component  of the  business  combination.  SFAS 141RASC  topic  805  will  be  applicable
prospectively  to business  combinations for which the acquisition date is on or
after the beginning of the first annual  reporting  period beginning on or after
December  15,  2008.  SFAS 141RASC topic 805 would have an impact on  accounting  for any
businesses acquired after the effective date of this pronouncement.  The Company
believes  that the  adoption  of ASC  topic  805  could  have an  impact  on the
accounting for any future acquisitions, if one were to occur.



                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               SEPTEMBER 30, 2009
                                  (UNAUDITED)


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Recent Accounting Pronouncements (Continued)
- --------------------------------

In  December  2007,  the FASB  issued  ASC topic 810  (formerly  SFAS No.  160,  "Noncontrolling160),
Noncontrolling  Interests in Consolidated  Financial  Statements - An Amendment of
ARB No. 51" ("SFAS  160").
SFAS 16051. ASC topic 810 establishes accounting and reporting standards for the
noncontrolling  interest  in a  subsidiary  (previously  referred to as minority
interests).  SFAS
160ASC topic 810 also requires that a retained noncontrolling interest
upon the  deconsolidation  of a  subsidiary  be  initially  measured at its fair
value.  Upon  adoption of SFAS 160,ASC topic 810,  the Company will be required to report
its noncontrolling interests as a separate component of stockholders'stockholders equity. The
Company  will  also  be  required  to  present  net  income   allocable  to  the
noncontrolling  interest and net income  attributable to the stockholders of the
Company separately in its consolidated statements of income. Currently, minority
interests  are  reported as a liability  in the  Company'sCompanys  consolidated  balance
sheets  and  the  related  income  attributable  to the  minority  interests  is
reflected as an expense in arriving at net loss.  SFAS 160ASC topic 810 is effective for
fiscal years,  and interim  periods  within those fiscal years,  beginning on or
after  December 15, 2008.  SFAS 160ASC topic 810  requires  retroactive  adoption of the
presentation and disclosure  requirements for existing minority  interests.  All
other requirements of SFAS 160ASC topic 810 shall be applied prospectively.  The Company
has  adopted  SFAS No. 160ASC topic 810 for our  fiscal  year  beginning  July 1,  2009,  and itthe
adoption did not have any impact on the Company's consolidated financial statements


                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                 MARCH 31, 2009
                                   (UNAUDITED)


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Recent Accounting Pronouncements (Continued)
- --------------------------------------------

In March  2008,  the FASB issued SFAS No.  161,  "Disclosures  about  Derivative
Instruments and Hedging Activities-an amendment of FASB Statement No 133" ("SFAS
No.  161").  SFAS No. 161 changes the  disclosure  requirements  for  derivative
instruments and hedging  activities.  Entities are required to provide  enhanced
disclosures about (a) how and why an entity uses derivative instruments, (b) how
derivative instruments and related hedged items are accounted for under SFAS No.
133 and its related  interpretations,  and (c) how  derivative  instruments  and
related hedged item affect an entity'sCompanys financial position,  financial performance
andresults of
operations or cash flows.  The  guidance  in SFAS No.  161 is  effective  for  financial
statements  issued for fiscal years and interim periods beginning after November
15, 2008, with early application encouraged. This Statement encourages, but does
not require,  comparative  disclosures for earlier periods at initial  adoption.
The  Company  has  adopted  SFAS No.  161 and it did not have any  impact on the
Company's consolidated financial statements.

In May 2008, the FASB issued SFAS No. 162, "The Hierarchy of Generally  Accepted
Accounting  Principles".  SFAS No. 162  identifies  the  sources  of  accounting
principles  and the framework  for  selecting  the  principles to be used in the
preparation  of  financial  statements  of  nongovernmental  entities  that  are
presented in conformity  with generally  accepted  accounting  principles in the
United  States.  It is effective  60 days  following  the SEC's  approval of the
Public Company  Accounting  Oversight  Board  amendments to AU Section 411, "The
Meaning of Present  Fairly in  Conformity  With  Generally  Accepted  Accounting
Principles".  The adoption of this  statement is not expected to have a material
effect on the Company's consolidated financial statements.

In October 2008, the FASB issued ASC topic 820 (formerly FASB Staff Position No.
FAS 157-3, "Determining157-3),  Determining the Fair Value of a Financial Asset in a Market That Is
Not Active"  ("FSP
157-3"),Active, which clarifies the application of SFAS 157ASC topic 820 when the market for
a financial  asset is inactive.  Specifically,  FSP  157-3ASC topic 820  clarifies how (1)
management'smanagements  internal  assumptions  should be considered in measuring fair value
when observable data are not present,  (2) observable market information from an
inactive  market should be taken into account,  and (3) the use of broker quotes
or  pricing  services  should  be  considered  in  assessing  the  relevance  of
observable  and  unobservable  data to measure  fair value.  The guidance in FSP
157-3ASC
topic 820 is  effective  immediately  and did not have a material  impact on the
Company'sCompanys condensed  consolidated  financial  statements.
                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                 MARCH 31, 2009
                                   (UNAUDITED)


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Recent Accounting Pronouncements (Continued)
- --------------------------------------------

In June 2008, the FASB ratifiedissued ASC topic 815 (formerly  Emerging Issue Task Force
("EIFT)  07-5,
"Determining07-5),  Determining Whether an Instrument (or an Embedded Feature) is Indexed to
an Entity'sEntitys Own Stock" ("EIFT 07-5).  EITF 07-5Stock. ASC topic 815 provides  framework for determining  whether
an instrument is indexed to an entity'sentitys own stock. EIFT 07-5ASC topic 815 is effective for
fiscal  years  beginning  after  December  15,  2008.  The Company is  currently
evaluating  the  impact of the  adoption  of EIFT 07-5ASC  topic 815 on its  consolidated
financial position and results of operations.

In December  2007,  the FASB issued SFAS No. 160,  Noncontrolling  Interests  in
Consolidated Financial Statements,  an amendment of Accounting Research Bulletin
ARB No. 51,  Consolidated  Financial  Statements  (SFAS No.  160) . SFAS No. 160
requires  (i)  that  non-controlling  (minority)  interests  be  reported  as  a
component of  stockholders'  equity,  (ii) that net income  attributable  to the
parent and to the  non-controlling  interest  be  separately  identified  in the
consolidated statement of operations, (iii) that changes in a parent's ownership
interest while the parent retains its  controlling  interest be accounted for as
equity transactions,  (iv) that any retained  non-controlling  equity investment
upon the  deconsolidation  of a subsidiary  be initially  measured at fair value
and, (v) that  sufficient  disclosures  are provided  that clearly  identify and
distinguish  between  the  interests  of the  parent  and the  interests  of the
non-controlling  owners.  SFAS No. 160 is  effective  for  financial  statements
issued for fiscal years  beginning  after December 15, 2008, and interim periods
within those fiscal years. We adopted SFAS No. 160 for our fiscal year beginning
January 1, 2009,  and the adoption  did not have any impact on our  consolidated
financial position, results of operations and cash flows.

In April 2009,  the FASB issued Staff  Position  No.ASC topic 270 (formerly FAS 107-1 and APB 28-1,28-1),
Interim Disclosures about Fair Value of Financial Instruments (FSP FAS 107-1 and
APB 28-1).  FSP FAS 107-1 and APB 28-1 extends the  disclosure  requirements  of
SFAS 107 to interim  period  financial  statements,  in addition to the existing
requirements  for  annual  periods  and  reiterates  SFAS 107's  requirement  to
disclose the methods and  significant  assumptions  used to estimate fair value.
FSP FAS 107-1 and APB 28-1 is  effective  for our  interim  and  annual  periods
commencing with our June 30, 2009 consolidated  financial statements and will be
applied on a prospective basis. We believe the adoption of FSP FAS 107-1 and APB
28-1 will not have a material impact on consolidated financial position, results
of operations and cash flows.

In April  2009,  the FASB issued  SFAS 107-1 and APB 28-1,  Interim  Disclosures
about Fair Value of Financial  Instruments (SFAS 107-1).Instruments. SFAS 107-1 amends
FASB No. 107, Disclosures about Fair Value of Financial Instruments,  to require
disclosures  about fair value of  financial  instruments  for interim  reporting
periods of publicly traded companies as well as in annual financial  statements.
SFAS also amends APB Opinion No. 28,  Interim  Financial  Reporting,  , to require
those  disclosures  in summarized  financial  information  at interim  reporting
periods.  SFAS 107-1ASC topic 270 is effective for interim and annual  reporting periods ending after
June 15, 2009.  We do not believe theThe adoption of this standard willdid not have a material  impact on
the Companys  consolidated  financial  position,  results of operations and cash
flows.  The carrying value of our cash and cash  equivalents  approximates  fair
value because  these  instruments  have  original  maturities of three months or
less.



                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               SEPTEMBER 30, 2009
                                  (UNAUDITED)


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Recent Accounting Pronouncements (Continued)
- --------------------------------

In May 2009, the FASB issued ASC 855 (formerly SFAS No. 165), Subsequent Events.
This Statement  establishes  general standards of accounting for and disclosures
of  events  that  occur  after  the  balance  sheet  date but  before  financial
statements are issued or are available to be issued.  It requires the disclosure
of the date  through  which an entity has  evaluated  subsequent  events and the
basis for that date and is effective for interim and annual periods ending after
June 15,  2009.  The  adoption of ASC 855 did not have a material  impact on the
Companys condensed consolidated financial statements.

In June  2009,  the  FASB  issued  ASC 105  (formerly  SFAS No.  168),  The FASB
Accounting  Standards  Codification  and the  Hierarchy  of  Generally  Accepted
Accounting  Principles.  ASC 105 will become the single source of  authoritative
nongovernmental   U.S.   generally   accepted   accounting   principles  (GAAP),
superseding  existing FASB,  American  Institute of Certified Public Accountants
(AICPA),  EITF,  and related  accounting  literature.  ASC 105  reorganizes  the
thousand of GAAP  pronouncements  into roughly 90 accounting topics and displays
them using a consistent  structure.  Also  included is relevant  Securities  and
Exchange  Commission  guidance  organized  using the same  topical  structure in
separate sections. ASC 105 will be effective for financial statements issued for
reporting periods that end after September 15, 2009. As the codification was not
intended to change or alter  existing U.S.  GAAP, it does not have any impact on
our consolidated financial position, results of operations and cash flows.

In April  2008,  the  FASB  issued  ASC  topic  350  (formerly  FSP FAS  142-3),
Determination of the Useful Life of Intangible  Assets. ASC topic 350 amends the
factors that should be considered in developing renewal or extension assumptions
used to  determine  the useful life of an  intangible  asset under SFAS No. 142,
Goodwill  and Other  Intangibles  (SFAS 142).  ASC topic 350 aims to improve the
consistency  between the useful life of an intangible  asset as determined under
SFAS 142 and the period of expected cash flows used to measure the fair value of
the asset  under  SFAS No.  141,  Business  Combinations,  and other  applicable
accounting literature.  ASC topic 350 will be effective for financial statements
issued for fiscal years  beginning  after December 15, 2008, and interim periods
within those fiscal  years.  The adoption of this  pronouncement  did not have a
material impact on the Companys condensed consolidated financial statements.

In June 2009,  the FASB issued ASC 860 (formerly  SFAS No. 166),  Accounting for
Transfers of Financial  Assets an amendment of FASB  Statement  No. 140, ASC 860
requires additional  disclosures concerning a transferors continuing involvement
with  transferred  financial  assets.  ASC  860  eliminates  the  concept  of  a
qualifying special-purpose entity and changes the requirements for derecognizing
financial assets. ASC 860 is effective for fiscal years beginning after November
15, 2009.  The Company is currently  evaluating  the impact that the adoption of
ASC 860 will have on its condensed consolidated financial statements.



                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               MARCH 31,SEPTEMBER 30, 2009
                                  (UNAUDITED)


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)(Continued)

Recent Accounting Pronouncements (Continued)
- --------------------------------

In June 2009,  the FASB issued ASC 810  (formerly  SFAS No. 167),  Amendments to
FASB  Interpretation  (FIN) No.  46(R),  which  changes how a  reporting  entity
determines  when  an  entity  that  is  insufficiently  capitalized  or  is  not
controlled  through  voting (or  similar  rights)  should be  consolidated.  The
determination of whether a reporting  entity is required to consolidate  another
entity is based on, among other things, the other entitys purpose and design and
the reporting  entitys ability to direct the activities of the other entity that
most significantly impact the other entitys economic  performance.  ASC 810 will
require  a  reporting  entity  to  provide  additional   disclosures  about  its
involvement with variable interest entities and any significant  changes in risk
exposure  due to that  involvement.  A  reporting  entity  will be  required  to
disclose  how its  involvement  with a  variable  interest  entity  affects  the
reporting  entitys financial  statements.  ASC 810 is effective for fiscal years
beginning  after  November 15,  2009,  and interim  periods  within those fiscal
years.  Management is currently  evaluating the  requirements of ASC 810 and has
not yet determined the impact on the Companys condensed  consolidated  financial
statements.

In September 2009, the FASB reached final consensus on a new revenue recognition
standard, ASC topic 815(formerly EITF Issue No. 08-1), Revenue Arrangements with
Multiple  Deliverables.  ASC topic 815  addresses  how to  determine  whether an
arrangement  involving  multiple  deliverables  contains  more  than one unit of
accounting,  and how the arrangement consideration should be allocated among the
separate units of accounting. This Issue is effective for fiscal years beginning
after June 15, 2010 and may be applied  retrospectively or prospectively for new
or materially modified arrangements.  In addition,  early adoption is permitted.
The Company is currently evaluating the potential impact of ASC topic 815 on its
condensed consolidated financial statements.

In September 2009, the EITF reached final consensus on a new revenue recognition
standard,  ASC topic 350 (formerly EITF 09-3),  Applicability of AICPA Statement
of Position 97-2 to Certain  Arrangements  That Contain Software  Elements.  ASC
topic 350 amends the scope of AICPA Statement of Position 97-2, Software Revenue
Recognition to exclude tangible  products that include software and non-software
components   that   function   together  to  deliver  the   products   essential
functionality.  This Issue shall be applied on a  prospective  basis for revenue
arrangements entered into or materially modified in fiscal years beginning on or
after June 15, 2010.  Earlier  application is permitted as of the beginning of a
companys  fiscal year provided the company has not previously  issued  financial
statements  for any period  within  that year.  An entity  shall not elect early
application of this Issue unless it also elects early application of Issue 08-1.
The Company is currently evaluating the potential impact of ASC topic 350 on its
condensed consolidated financial statements.

Reclassifications
- -----------------

Certain prior year amounts have been reclassified to conform to the current year
presentation.  The  reclassifcationsreclassifications  did  not  have  any  effect  on  reported
consolidated net losses for any periods presented.



                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               SEPTEMBER 30, 2009
                                  (UNAUDITED)


NOTE 3 - MEDICAL RECEIVABLES, ACCOUNTS RECEIVABLE AND MANAGEMENT FEE RECEIVABLE

Medical Receivables
- -------------------

The  Company  was  assigned  medical  receivables  valued  at  $11,775,000,   in
connection with the  satisfaction  of the management  fees and termination  fees
related to a  Termination  and  Replacement  Agreement  dated May 23, 2005.  The
balance of the net medical  receivables  as of  March 31, 2009 was $555,000.  As of
March 31,September  30, 2009 and June 30,
2008,2009 was $316,000 and $374,000,  respectively. As of September 30, 2009 and June
30, 2009, the Company recorded anCompanys  allowance for doubtful  accounts of $1,221,500totaled  $1,383,500 and
$769,000,$1,343,500, respectively, on these receivables.

Accounts Receivable and Management Fee Receivable
- -------------------------------------------------

Receivables, net is comprised of the following at March 31,September 30, 2009:
                            (000's(000s Omitted)

                         Gross          Allowance Gross         for
                       Receivable     doubtful
                                    Receivable accounts       Net
                       -----------   ------------    ---------------------     -----------------     -------
Receivables from
equipmentEquipment sales and
service contracts      $   6,7737,564          $   1,5672,408         $ 5,206
                                    ===========   ============    ===========5,156
                       ==========     =================     =======

Receivables from
equipment sales and
service contracts-
related parties        $     1,238179          $    619-            $   619
                                     =========    ============    ============179
                       ==========     =================     =======

Management fee
receivables            $   8,3698,522          $   4,3185,218         $ 4,051
                                     =========    ============    ============3,304
                       ==========     =================     =======

Management fee
receivables from
related medical
practices ("PC's"PCs")      $   3,8583,115          $   2,3781,095         $ 1,480
                                     =========    ============    ============2,020
================       ==========     =================     =======

The Company's customers are concentrated in the healthcare industry.

The  Company's  receivables  from  the  related  and  non-related   professional
corporations (PC's) substantially  consists of fees outstanding under management
agreements.  Payment of the  outstanding  fees is dependent on collection by the
PC's of fees from third party medical reimbursement  organizations,  principally
insurance companies and health management organizations.

As of June 22,  2007,  an  unrelated  third  party  purchased  the  stock of the
professional  corporations  owning  the  eight  New York  sites  managed  by the
Company, previously owned by Dr. Raymond V. Damadian, the President, Chairman of
the Board and principal  stockholder of Fonar.  In connection with the sale, new
management  agreements were substituted for the existing management  agreements,
providing,  however,  for the same  management  services.  The fees  starting in
fiscal 2008,  however,  are currently fixed monthly fees in amounts ranging from
$45,000 to $125,000 per month.  Dr.  Damadian still owns the four MRI facilities
in Georgia  and  Florida  managed by the  Company.  No MRI  facilities  or other
medical facilities are owned by the Company.


                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                 MARCH 31, 2009
                                   (UNAUDITED)


NOTE 3 - MEDICAL RECEIVABLES, ACCOUNTS RECEIVABLE AND MANAGEMENT FEE RECEIVABLE
(CONTINUED)


Collection by the Company of its management fee  receivables  may be impaired by
the   uncollectibility  of  the  PC'sPCs  medical  fees  from  third  party  payors,
particularly   insurance  carriers  covering  automobile  no-fault  and  workers
compensation  claims due to longer  payment  cycles and  rigorous  informational
requirements and certain other disallowed claims.  Approximately 48% and 44%49% of the PC's
net revenues for both the ninethree months ended  March 31,September 30, 2009 and 2008,
respectively,  were
derived  from  no-fault  and  personal  injury  protection  claims.  The Company
considers  the aging of its accounts  receivable  in  determining  the amount of
allowance  for  doubtful  accounts  and  contractual  allowances.   The  Company
generally takes all legally  available steps to collect its receivables.  Credit
losses  associated  with  the  receivables  are  provided  for in the  unaudited
condensed  consolidated  financial  statements and have historically been within
management's expectations.

Net  revenues  from  management  and other fees  charged to the  related  P.C.'s
accounted for approximately  7.4% and 10.0% of the consolidated net revenues for
the nine months ended March 31, 2009 and 2008,  respectively.  Product sales and
service repair fees from related parties amounted to approximately 3.3% and 2.9%
of  consolidated  net revenues for the nine months ended March 31, 2009 and 2008
respectively.

HMCA  entered  into a management  agreement  in  September  2007 with  Integrity
Healthcare  Management  Inc  ("Integrity").  Under the  terms of the  agreement,
Integrity provided the billings and collections for HMCA's facilities as well as
assist  in the  management  of the  facilities.  Integrity  was  to  receive  as
compensation an annual fee equal to one-half of the increase in the consolidated
cash flow of HMCA and the  facilities  over the period from July 1, 2006 through
June 30, 2007. The original term of the agreement was one year with an automatic
year to year renewal, but may be terminated by either party without cause at the
end of any  year.  During  June  2008,  HMCA  terminated  the  agreement  and no
management  fees were earned by  Integrity.  Integrity is a subsidiary of Health
Diagnostics,  LLC. The director of Health Diagnostics, LLC, Timothy Damadian, is
a son of the  President  and  Chief  Executive  Officer  of Fonar,  Dr.  Raymond
Damadian.   Commencing  with  June  2008,  however,  the  Company  hired  Health
Diagnostics,  LLC, the parent  company of Integrity,  to perform all billing and
collection  procedures  on its  behalf.  The Company has agreed to pay 6% of all
adjusted  deposits for these  services.  Amounts charged to HMCA during the nine
months  ended  March 31,  2009  under  this  agreement  totaled  $794,006.  HMCA
terminated the billing and collection agreement as of April 30, 2009.



                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               MARCH 31,SEPTEMBER 30, 2009
                                  (UNAUDITED)


NOTE 3 - MEDICAL RECEIVABLES,  ACCOUNTS RECEIVABLE AND MANAGEMENT FEE RECEIVABLE
     (CONTINUED)

Unaudited Financial Information of Unconsolidated Managed Medical Practices
- ---------------------------------------------------------------------------

Audited  financial  information  related(Continued)

Net revenues from management and other fees charged to the unconsolidated   related PCs accounted
for approximately 10.6% and unrelated P.C.'s managed by10.7% of the Company is not available.  Substantially  all of
these medical  practices' books and records are maintained on a cash basis, they
depreciate  their  equipment on an accelerated  tax basis and have a December 31
year end.

Summarized  statement  of  operations  dataconsolidated net revenues for the three
months ended March 31,September 30, 2009 and 2008, respectively.

Effective June 30, 2009,  Tallahassee  Magnetic Resonance Imaging,  PA, Stand Up
MRI of Boca Raton,  PA and Stand Up MRI &  Diagnostic  Center,  PA (all  related
medical  practices)  entered in a guaranty  for all  management  fees which were
indebted to the unconsolidated  medical  practices  managed byCompany. Each entity will jointly and severally guarantee to the
Company is as follows:

                     (000's omitted) (Income Tax-Cash Basis)
                                   For the three months ended March 31,
                                             2009       2008
                                           --------   --------
                   Patient Revenue - Net   $ 3,936    $ 4,603
                                           ========   ========
                   Income from Operations  $   104    $   172
                                           ========   ========
                   Net  Income             $    87    $    55
                                           ========   ========

Summarized statement of operations data for the nine months ended March 31,
2009 and 2008 relatedall payments due to the unconsolidated medical practices managed by the
Company is as follows:

                     (000's omitted) (Income Tax-Cash Basis)
                                   For the nine months ended March 31,
                                             2009       2008
                                           --------   --------
                   Patient Revenue - Net   $11,874    $12,955
                                           ========   ========
                   Loss from Operations    $(   31)   $(  306)
                                           ========   ========
                   Net  Loss               $(   83)   $(  698)
                                           ========   ========


                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                 MARCH 31, 2009
                                   (UNAUDITED)which have arisen under each  individual
management agreement.


NOTE 4 - INVENTORIES

Inventories  included in the accompanying  condensed  consolidated balance sheet
consist of the following:                (000's omitted)

                                        March 31,September 30,      June 30,
                                           2009              20082009
                                        -------------     ---------  ----------
        Purchased parts, components
          and supplies                    $ 2,5872,105         $ 1,8472,065
        Work-in-process                     1,206      1,409
                                        -------    -------1,347           1,107
                                        -------------     ---------
                                          $ 3,7933,452         $ 3,2563,172
                                        =============     =========  ==========


NOTE 5 - COSTS AND  ESTIMATED  EARNINGS ON  UNCOMPLETED  CONTRACTS  AND CUSTOMER
     ADVANCES

1)   Information  relating to uncompleted  contracts as of March 31,September 30, 2009 is
     as follows:

                                (000's omitted)
           Costs incurred on uncompleted contracts     $ 8,44410,329
           Estimated earnings                             5,3435,561
                                                       ---------
                                                         13,78715,890
     Less: Billings to date                              18,39217,214
                                                       ---------
                                                       $(4,605)$ (1,324)
                                                       =========

Included in the accompanying  unaudited condensed  consolidated balance sheet at
March 31,September 30, 2009 under the following captions:

           Costs and estimated earnings in excess of
             billings on uncompleted contracts         528$  1,212
     Less: Billings in excess of costs and estimated
             earnings on uncompleted contracts            5,133
                                                 --------
                                                 $(4,605)
                                                 ========2,536
                                                       ---------
                                                       $ (1,324)
                                                       =========

2)   Customer advances consist of the following as of March 31,September 30, 2009:

                                                Related
                                    Total       Party       Other
                                   --------    --------    --------
   Total Advances                  $ 27,11726,478    $  854-        $ 26,26326,478
   Less: Advances on contracts
        under construction           18,39217,214       -          18,39217,214
                                   --------    --------    --------
                                   $  8,7259,264    $  854-        $  7,8719,264
                                   ========    ========    ========


                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               MARCH 31,SEPTEMBER 30, 2009
                                  (UNAUDITED)


NOTE 6 -STOCKHOLDERS DEFICIENCY

Common Stock

During the three months ended September 30, 2009:

a)   The  Company   issued  10,000  shares  of  common  stock  to  employees  as
     compensation valued at $18,200 under a stock bonus plan.


NOTE 7 OTHER CURRENT LIABILITIES

Other current  liabilities in the accompanying  condensed  consolidated  balance
sheet consist of the following:

                                 (000's(000s omitted)

                                  March 31,September 30,       June 30,
                                      2009              2008
                                   ---------    ---------2009
                                  -------------     -------------
       Royalties                    $      623        $      623
Accrued salaries, commissions
   and payroll taxes                     1,073          9011,109               882
Accrued interest                           793          876947               901
Litigation accruals                        193               193
Sales tax payable                        2,687        2,5442,459             2,434
Legal and other professional fees          596          634784               675
Accounting fees                            360          503331               480
Insurance premiums                          177          41072                30
Penalty -  Sales tax                         657          632682               682
Penalty  - 401k plan  (see Note 11)        250               250
Purchase scanner                           165               440
Other                                      636          750
                                   ---------    ---------814               870
                                  -------------     -------------
                                    $    8,0458,429        $    8,316
                                   =========    =========8,460
                                  =============     =============



                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               MARCH 31,SEPTEMBER 30, 2009
                                  (UNAUDITED)


NOTE 7 -8 SALE OF CONSOLIDATED SUBSIDIARY AND INVESTMENT

Sale of Consolidated Subsidiary
- -------------------------------

On September 30, 2008,  the Company sold its 92.3% interest (to a related party)
in an  entity  that  provided  management  services  to a  diagnostic  center in
Bensonhurst, NY. The Company continues to manage other diagnostic centers in the
New York region.

The related third party  purchased all assets and assumed all liabilities of the
diagnostic center which included cash, the management fee receivable,  furniture
and fixtures and other  miscellaneous  assets.  The purchase price for the 92.3%
interest was $2,307,500 all of which was paid in cash at the time of closing.

The following is the  calculation of the gain on sale of the 92.3% interest in a
consolidated subsidiary:

                                 (000's(000s omitted)
            Selling Price -  Net cash paid:                          $  2,307

            Assets and liabilities sold:
            Cash                                         $   14
            Management fee receivable -net                  917
            Property and equipment  - net                       1
            Other assets                                     34
            Accounts payable                                (  16)(16)
            Minority interest                               (  91)(91)
                                                       ---------
            Subtotal                                                    859
                                                                  -----------------
            Gain on sale of consolidated subsidiary                $  1,448
                                                                  ==================



                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               MARCH 31,SEPTEMBER 30, 2009
                                  (UNAUDITED)


NOTE 7 - SALE OF CONSOLIDATED SUBSIDIARY AND SALE OF INVESTMENT (CONTINUED)

Sale of Consolidated Subsidiary (Continued)
- -------------------------------------------

On July 31, 2007,  the Company  sold its 50%  interest  (to an  unrelated  third
party) in an entity that provided  management services to a diagnostic center in
Orlando,  FL. The Company  continues to manage other  diagnostic  centers in the
Florida region.

The unrelated  third party  purchased all assets and assumed all  liabilities of
the diagnostic  center which  included  cash,  the  management  fee  receivable,
furniture and fixtures and other  miscellaneous  assets.  The purchase price for
the 50% interest was $4,500,000 and after closing costs the amount  received was
$4,257,000.

The  following is the  calculation  of the gain on sale of the 50% interest in a
consolidated subsidiary:

                                 (000's omitted)
          Selling Price:                                   $ 4,500
          Less: Closing costs                               (  243)
          Selling Price - Net cash paid :                    4,257

          Assets sold:
                Cash                             $   114
                Management fee
                    receivable                     1,166
                Property and
                     equipment - net                  23
                Other assets                          15
                Minority interest                   (456)
          Subtotal                                             862
                                                           -------
          Gain on sale of consolidated subsidiary          $ 3,395
                                                           =======
Sale of Investment
- ------------------

On July 31, 2007, the Company sold its 20% equity interest in an  unconsolidated
entity (management company for a diagnostic center) to an unrelated third party.
The selling price was $629,195.  The Company  realized a gain on the sale of the
equity interest of $571,161.

The gain was calculated as follows:

                                 (000's omitted)
          Selling Price:                           $ 629
                Less: Closing costs                 ( 58)
          Selling Price - Net cash paid              571

          Cost Basis                                -

          Gain on sale of investment               $ 571
                                                   =====


                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                 MARCH 31, 2009
                                   (UNAUDITED)


NOTE 89 - SEGMENT AND RELATED INFORMATION

The Company operates in two industry  segments - manufacturing and the servicing
of medical equipment and management of diagnostic imaging centers.

The accounting  policies of the segments are the same as those  described in the
summary of significant  accounting policies as disclosed in the Company'sCompanys 10-K as
of June  30,  2008.2009.  All  inter-segment  sales  are  market-based.  The  Company
evaluates performance based on income or loss from operations.

Summarized financial information concerning the Company's reportable segments is
shown in the following table:

                                 (000's omitted)
                                                       Management
                                                       of Diagnostic
                                            Medical    Imaging
                                            Equipment  Centers        Totals
                                            ---------  -------------  -------------------
For the three months ended March 31,Sept. 30, 2009:

Net revenues from external customers        $  8,7784,961     $    2,4782,530    $  11,2567,491
Inter-segment net revenues                  $    245232     $     -       $    245
Income232
(Loss) from operations                      $   816(903)    $     (54)(519)   $ 762(1,422)
Depreciation and amortization               $    262229     $      168137    $    430366
Capital expenditures                        $    190195     $        125    $    202200
Identifiable assets                         $ 17,298     $   10,154    $ 27,452

For the three months ended March 31,Sept. 30, 2008:

Net revenues from external customers        $  5,1334,013     $    2,9382,771    $  8,0716,784
Inter-segment net revenues                  $    208272     $     -       $    208
Loss272
(Loss) Income from operations               $ (2,510)(1,860)    $       (211)12    $ (2,721)(1,848)
Depreciation and amortization               $    353267     $      230168    $    583435
Capital expenditures                        $    353     $     28      $    381

For the nine months ended March 31, 2009:

Net revenues from external customers        $ 21,632     $  7,699      $ 29,331
Inter-segment net revenues                  $    762210     $     -       $    762
Income (Loss) from operations               $    207     $ (  593)     $   (386)
Depreciation and amortization               $    793     $    504      $  1,297
Capital expenditures                        $    588     $     16      $    604210
Identifiable assets  June 30, 2009          $ 17,63017,302     $   12,00311,057    $ 29,633

For28,359


NOTE 10  SUPPLEMENTAL CASH FLOW INFORMATION

During the ninethree months ended  March 31, 2008:

Net revenues from external customers         $18,328     $  9,093      $ 27,421
Inter-segment net revenues                  $    662     $   -         $    662
Loss from operations                        $ (9,944)    $   (759)     $(10,703)
DepreciationSeptember 30, 2009 and  amortization               $  1,032     $    695      $  1,727
Capital expenditures                        $    793     $    102      $    895
Identifiable assets - JuneSeptember  30, 2008,  $ 19,203     $ 16,022      $ 35,225the
Company paid $34,000 and $127,000 for interest, respectively.



                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               MARCH 31,SEPTEMBER 30, 2009
                                  (UNAUDITED)


NOTE 9 - SUPPLEMENTAL CASH FLOW INFORMATION

During the nine months ended March 31, 2009 and March 31, 2008, the Company paid
$278,000 and $178,000 for interest, respectively.

The Company  paid  $36,000 and $0 for income  taxes during the nine months ended
March 31, 2009 and 2008, respectively.


NOTE 10 -11 COMMITMENTS AND CONTINGENCIES

Litigation
- ----------

The Company is subject to legal proceedings and claims arising from the ordinary
course  of its  business,  including  personal  injury,  customer  contract  and
employment  claims. In the opinion of management,  the aggregate  liability,  if
any, with respect to such actions,  will not have a material  adverse  effect on
the consolidated financial position or results of operations of the Company.

Other Matters
- -------------

In March 2007,  the Company and New York State  taxing  authorities  conducted a
conference  to  discuss  a sales  tax  matter  to  determine  if  certain  sales
transactions are subject to sales tax withholdings.  In fiscal 2007, the Company
recorded a provision of $250,000 to cover any potential tax liability  including
interest. This matter was settled in May of 2009 with no payment required by the
Company.  The Company  will  reversereversed the accrual for this matter in the quarter ended
June 30, 2009.

The Company is also  delinquent in filing sales tax returns for certain  states,
for which the Company has  transacted  business.  As of March 31,September 30, 2009,  the
Company has recorded tax obligations of  approximately  $2,025,000$2,066,000 plus interest
and  penalties  of  approximately  $1,310,000.$1,420,000.  The Company is in the process of
determining the regulatory requirements in order to become compliant.

The Company has determined  they may not be in compliance with the Department of
Labor and Internal  Revenue Service  regulations  concerning the requirements to
file Form 5500 to report  activity  of its 401(k)  Employee  Benefit  Plan.  The
filings do not require the  Company to pay tax,  however  they may be subject to
penalty  for  non-compliance.  The  Company  has  recorded  provisions  for  any
potential penalties totaling $250,000. Such amount is the Company'sCompanys best estimate
of potential  penalties.  Management  is unable to determine the outcome of this
uncertainty.  The Company has engaged  outside counsel to handle such matters to
determine the necessary  requirements to ensure compliance.  Such non-compliance
could impact the  eligibility  of the plan.  At this time the outcome  cannot be
determined.

The Companys management fees are dependent on collection by the PCs of fees from
reimbursements from Medicare,  Medicaid, private insurance, no fault and workers
compensation  carriers,  self-pay and other third-party  payors. The health care
industry is experiencing the effects of the federal and state  governments trend
toward cost  containment,  as government  and other  third-party  payors seek to
impose lower  reimbursement  and utilization rates and negotiate reduced payment
schedules with providers.  The cost containment measures,  consolidated with the
increasing  influence of managed-care payors and competition for patients,  have
resulted in reduced rates of reimbursement  for services provided by the Company
from time to time. The Companys future revenues and results of operations may be
adversely impacted by future reductions in reimbursement rates.


                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               MARCH 31,SEPTEMBER 30, 2009
                                  (UNAUDITED)


NOTE 10 -11 COMMITMENTS AND CONTINGENCIES Continued(Continued)

Other Matters (Continued)
- -------------

In 2009, the Obama administration announced its intentions for healthcare reform
in the United States. The plan includes providing  healthcare  coverage for some
40 million  uninsured  Americans.  The plan calls for, among other things.  More
vigilant  control  of  healthcare  utilization,   including  diagnostic  imaging
services.  The use of radiology  benefit  managers,  or RBMs,  has  increased in
recent years.  It is common practice for health  insurance  carriers to contract
with RMBs to manage  utilization  of  diagnostic  imaging  procedures  for their
insureds.  In many cases, this leads to lower utilization of imaging  procedures
based on a determination of medical  necessity.  The efficacy of RBMs is still a
highly  controversial  topic.  The Company  cannot  predict  whether the current
administrations  healthcare plan and the use of RBMs will negatively  impact its
business, but it is possible that the Companys financial position and results of
operations could be negatively affected by increased utilization of RBMs.

While the  Company has  prepared  certain  estimates  of the impact of the above
discussed  changes and proposed  changes,  it is not possible to fully  quantify
their impact on its business. There can be no assurance that the impact of these
changes  will not be  greater  than  estimated  or that any future  health  care
legislation  or  reimbursement  changes will not  adversely  affect the Companys
business.

NASDAQ Notice of Non-compliance
- -------------------------------

The Company's stockholder'sCompanys  stockholders  deficiency was $4.2$4.7 million as of September 30, 2009
and $2.9  million  as of June 30, 2008 and
$3.0 million as of March 31,  2009.  NASDAQ  had  granted  the  Company  an
extension  to  April 9,October  5,  2009  to  evidence   compliance   with  the  minimum
stockholders'stockholders  equity requirement or minimum net income requirement for continued
listing on the NASDAQ Capital Market.  Although  the  Company  was unable to raise the equity
financing  necessary to do so, the Company'sThe Companys common stock continues to be
listed pendingdue to its appeal to the NASDAQ Listing and Hearing  Review Council  requesting
an  extension  until  after  the filing of ourits Form 10-K for fiscal  2009,  to
demonstratewhich  demonstrated
compliance with one or morethe minimum net income requirements of the continued listing requirements.NASDAQ Capital Market.


NOTE 11 - NOTES RECEIVABLE

On August 8, 2008, the Company  signed a modification  agreement with regards to
the Asset Purchase Agreement with Health Plus. Under the modification  agreement
Health  Plus made a  $2,000,000  principal  payment  on the  promissory  note in
exchange for a discount on the original note of $1,000,000.

The original  promissory note ("Note") was modified to $2,378,130  payable in 60
consecutive  months in equal  installments of principal and interest of $47,090.
The  Note is  secured  by a first  lien on all of the  assets  of  Health  Plus,
including its accounts receivable and is subject to prepayment provisions to the
extent  Health Plus  resells all or part of the assets and  business or utilizes
the assets sold as  collateral  in any debt  financing.  The note  provides  for
interest at 7% per annum. The Company recorded a change to earnings representing
the net discount on this note of $658,351 on this transaction during the quarter
ended June 30, 2008.


NOTE 12 - LIFE  INSURANCE


During the three months ended March 31, 2009, the Company  borrowed $1.3 million
against the cash surrender value of a whole life insurance policy on the life of
the Company's Chief Executive Officer.


NOTE 13 - LICENSE FEES AND ROYALTIES

In July 2000,  the Company  entered into a  non-exclusive  sales  representative
agreement with an unrelated third party. The agreement  requires the third party
to sell at least two Fonar MRI  scanners or if it does not,  pay an amount equal
to the Company'sCompanys  gross margin on the unsold MRI scanner(s).  The third party has
not sold any scanners in the past two contract years.  The Company  received the
gross margin payment on two scanners of  approximately  $1.2 million in November
2007  and is  shown  in  the  Company's  condensed  consolidated  statements  of
operations  as revenue,  license  fees and  royalties  for the nine months ended
March 31, 2008.scanners.  The Company  received
the gross margin payment on one scanner of approximately  $585,000$585,493 in November 2008 and applied
a previously received deposit for two other scannersgross margin payments for a total of
$1.8 million shown as license fees
and royalties$1,755,493  which was included in revenue for the nineyear ended June 30, 2009.  The
Company  received the last gross margin payment of $585,493 in July 2009,  which
has been  included in revenue for the three months ended  March 31,September 30, 2009. As
of April 2009, this agreement has expired.




                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               SEPTEMBER 30, 2009
                                  (UNAUDITED)

NOTE 13 - INCOME TAXES

Effective  January 1, 2007, the Company  adopted the provisions of ASC topic 740
(formerly  FASB  Interpretation  No. 48/FASB  Statement No. 109,  Accounting for
Uncertainty in Income Taxes).  ASC topic 740 prescribes a recognition  threshold
and  a  measurement  attribute  for  the  financial  statement  recognition  and
measurement  of tax  positions  taken or expected to be taken in a corporate tax
return.   For  those  benefits  to  be  recognized,   a  tax  position  must  be
more-likely-than-not  to be sustained upon  examination  by taxing  authorities.
Differences  between tax positions taken or expected to be taken in a tax return
and the benefit  recognized  and  measured  pursuant to the  interpretation  are
referred to as  unrecognized  benefits.  A liability is recognized (or amount of
net operating loss  carryforward  or amount of tax refundable is reduced) for an
unrecognized  tax benefit because it represents an enterprises  potential future
obligation to the taxing authority for a tax position that was not recognized as
a result of applying the provisions of ASC topic 740.

In accordance  with ASC topic 740,  interest costs related to  unrecognized  tax
benefits are required to be calculated (if  applicable)  and would be classified
as Interest  expense,  net.  Penalties  if  incurred  would be  recognized  as a
component of Selling, general and administrative expenses.

The Company files  corporate  income tax returns in the United States  (federal)
and in various state and local jurisdictions.  In most instances, the Company is
no longer  subject to federal,  state and local income tax  examinations  by tax
authorities for years prior to 2004.

The adoption of the  provisions of ASC topic 740 did not have a material  impact
on the Companys consolidated financial position and results of operations.  Upon
the adoption and as of September  30, 2009, no liability  for  unrecognized  tax
benefits  was  required  to  be  recorded.  The  Company  does  not  expect  its
unrecognized tax benefit position to change during the next 12 months.

The  Company  recognized  a deferred  tax asset of $867,120  and a deferred  tax
liability  of $867,120  as of  September  30,  2009,  primarily  relating to net
operating loss carryforwards of approximately  $167,612,000  available to offset
future taxable income through 2029. The net operating  losses begin to expire in
2012 for federal tax purposes and in 2012 for state income tax purposes.

The ultimate  realization  of deferred tax assets is dependent on the generation
of future taxable income during the periods in which those temporary differences
become deductible. The Company considers projected future taxable income and tax
planning strategies in making this assessment.  At present, the Company does not
have a sufficient history of income to conclude that it is  more-likely-than-not
that the  Company  will be able to realize  all of its tax  benefits in the near
future and therefore a valuation allowance was established for the full value of
the deferred tax asset.

A valuation  allowance will be maintained  until  sufficient  positive  evidence
exists to support the  reversal of any portion or all of the  valuation.  Should
the Company become  profitable in future periods with  supportable  trends,  the
valuation allowance will be reversed accordingly.




                       FONAR CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               SEPTEMBER 30, 2009
                                  (UNAUDITED)


NOTE 14  SUBSEQUENT EVENTS

On October 27, 2009,  the Company  entered into an agreement with Mountain Crest
Ventures  LLC to  assign  the  promissory  note from  Health  Plus for the Asset
Purchase  Agreement.  The Company  received  $1,580,862,  which  represented the
remaining principal balance less a discount of $350,000. Mountain Crest Ventures
LLC  retains  all rights  under the  original  promissory  note to  collect  all
remaining  payments  due.  The Company  recorded  the  $350,000  discount in the
financial  statements  for the three months  ended  September  30,  2009.  As of
September  30, 2009,  the  remaining  balance due under the note  receivable  of
$1,580,862 was reclassified all to current assets.

The Company has evaluated  subsequent events through November 23, 2009, which is
the date the Company filed its quarterly report on Form 10Q for the period ended
September 30, 2009 with the  Securities  and Exchange  Commission.  There are no
further subsequent events for disclosure.


Item 2. MANAGEMENT'S2.MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
     OPERATIONS.

For the ninethree month period ended  March 31,September  30, 2009, we reported a net incomeloss of
$1.1$1.7  million on revenues of $29.3$7.5 million as compared to net loss of $6.7
million$450,000 on
revenues of $27.4  million for the nine month  period ended March 31,
2008.

     For the three month period ended March 31, 2009,  we reported net income of
$730,000 on revenues of $11.3 million as compared to net loss of $2.7 million on
revenues of $8.1$6.8 million for the three month period  ended  March 31,September  30, 2008.
Notwithstanding  the  increased net loss for the first quarter of fiscal 2010 as
compared to the first quarter of fiscal 2009 our operating results improved.  We
recognized  an  operating  loss of $1.4 million for the three month period ended
September 30, 2009  compared to an operating  loss of $1.8 million for the three
month period ended September 30, 2008. The principal  reason for the smaller net
loss in the first  quarter of fiscal 2009 as  compared  to the first  quarter of
fiscal 2010 was that during the first  quarter of fiscal 2009,  we  recognized a
gain of $1.4  million  on the  sale of a  consolidated  entity  managing  an MRI
scanning facility.

Overall,  our  revenues  increased  7.0%10.4% from $27.4$6.8  million for the first ninethree
months of fiscal 20082009 to $29.3$7.5 million for the first ninethree months of fiscal 2009.2010.
Most  significantly,  revenues from product  salesservice and repair fees increased 33.9%8.2%, from
$8.9$2.6  million for the first ninethree  months of fiscal 20082009 to $12.0$2.8 million for the
first ninethree months of fiscal 2009.  This sharp  increase  resulted  from the  Company's
increased production activity in the filling of orders for our MRI scanners.2010.

Due to the  increase in our  revenues  and a reduction of cost and  expenses,
our  operating  loss for the ninethree months
ended  March 31,September  30, 2009 was reduced as  compared  to the ninethree  months  ended
March 31,September 30, 2008 (a $386,000  operating loss for
the first nine months of fiscal 2009 as  compared to a $10.7$1.4 million  operating loss for the first ninethree months of
fiscal  2008)2010 as compared to a $1.8  million  operating  loss for the first three
months of fiscal 2009).  The decrease in the operating loss was  principally due
to a decreasean  increase  in  revenues  of 22.1% in our total costs and expenses,10.4%,  from $38.1$6.8  million for the first ninethree
months of fiscal 20082009 to $29.7$7.5 million for the first ninethree months of fiscal 2009.  In order to reduce  our net losses and
demands on our cash and other  liquid  reserves,  we  instituted  an  aggressive
program of cost  cutting at the end of fiscal 2008 and the  beginning  of fiscal
2009. Costs and expenses were reduced in most categories but most  significantly
in our  selling  general  and  administrative  expenses.  Overall,  there  was a
reduction of our selling, general and administrative expenses of 36%, from $15.5
million in the first nine  months of fiscal  2008 to $10.0  million in the first
nine months of fiscal 2009, resulting directly from our cost cutting program.

     In addition to the success of our cost  cutting  program in  improving  our
operating performance,  we also realized a gain on the sale in September 2008 of
our  92.3%  interest  in  a  consolidated   entity.   We  received  proceeds  of
approximately  $2.3 million and recognized a gain of approximately $1.4 million,
which also  improved  our  liquidity.  The entity was engaged in the business of
managing a MRI facility.  The principal reason,  however, for our net income for
the first nine months of fiscal 2009 of $1.1 million as compared to our net loss
for the  first  nine  months  of  fiscal  2008 of $6.7  million,  was due to the
improvement in our operations.

     We also are  monitoring  the  performance of our existing users in order to
establish teams to assist  underperforming  customers improve their scan volume.
In addition,  we have held seminars to assist  customers and the MRI  Facilities
managed by HMCA in their marketing  efforts and are in the process of developing
a web site to assist our customers in their marketing efforts.

     We implemented an aggressive program of cost cutting measures at the end of
fiscal  2008  and  the  beginning  of  fiscal  2009.   These  measures   include
consolidating  HMCA's office space with Fonar's office space,  reductions in the
size of our workforce,  compensation  and benefits,  as well as across the board
reduction of expenses.2010.

Forward Looking Statements

Certain   statements   made  in  this   Quarterly   Report   on  Form  10-Q  are
"forward-looking  statements"  (within  the  meaning of the  Private  Securities
Litigation  Reform Act of 1995) regarding the plans and objectives of Management
for  future  operations.  Such  statements  involve  known  and  unknown  risks,
uncertainties  and other factors that may cause our actual results,  performance
or achievements to be materially different from any future results,  performance
or achievements  expressed or implied by such  forward-looking  statements.  The
forward-looking  statements  included  herein are based on current  expectations
that involve  numerous  risks and  uncertainties.  Our plans and  objectives are
based, in part, on assumptions involving the expansion of business.  Assumptions
relating to the foregoing involve judgments with respect to, among other things,
future  economic,   competitive  and  market   conditions  and  future  business
decisions,  all of which are difficult or impossible to predict  accurately  and
many of which are beyond our control.  Although we believe that our  assumptions
underlying the forward-looking statements are reasonable, any of the assumptions
could  prove  inaccurate  and,  therefore,  there can be no  assurance  that the
forward-looking statements included in this Report will prove to be accurate. In
light of the significant uncertainties inherent in the forward-looking statement
included herein,  the inclusion of such information  should not be regarded as a
representation  by us or any other person that our  objectives and plans will be
achieved.

Results of Operations

We operate in two industry  segments:  the  manufacture and servicing of medical
(MRI) equipment,  our traditional business which is conducted directly by Fonar,
and diagnostic facilities management services, which is conducted through Fonar'sFonars
wholly-owned subsidiary, Health Management Corporation of America, which we also
refer to as HMCA.

Trends in the thirdfirst  quarter of fiscal 20092010 include an increase in product sales
revenues a decrease inand service and repair fees, anda decrease in management  fees, as well as a  decreasean
increase in our total costs and  expenses,  in particular in our selling,  general and administrative  expenses.cost related to
product  sales.  We will continue to focus on our  marketing  efforts to improve
sales performance in fiscal 2009.2010. In addition,  we will monitor our cost cutting
program and will continue to reduce costs as necessary.

For the three month period ended  March 31,September  30, 2009,  as compared to the three
month period ended March 31,September 30, 2008,  overall  revenues from MRI product sales
increased 162%10.6% ($6.21.6 million compared to $2.3 million).

     For the nine month  period  ended March 31,  2009,  as compared to the nine
month period  ended March 31,  2008,  overall  revenues  from MRI product  sales
increased 33.9% ($12.0 million compared to $8.9$1.4 million).

Service  revenues  for the three month  period  ended  March 31,September  30,  2009,  as
compared to the three month period ended  March 31,September  30, 2008  decreasedincreased by 5.9%8.2%
($2.62.8 million compared to $2.8$2.6 million). Unrelated party service and repair fees
decreasedincreased by 8.9%8.3% ($2.32.8  million  compared to $2.5  million)  and related  party
service and repair fees increased by 22.6% ($331,000 compared to $270,000).  The
reason  for the  decrease  in  unrelated  party  service  and  repair  fees  was
attributable to several customers  discontinuing  operations because of economic
conditions.remained  constant at $55,000.  We anticipate that there
will be increases in service revenues as warranties on installed scanners expire
over time.

Service  revenues  for the nine  month  period  ended  March 31,  2009,  as
compared to the nine month period  ended March 31, 2008  decreased by 4.0% ($7.9
million  compared  to $8.2  million).  Unrelated  party  service and repair fees
decreased by 6.8% ($6.9  million  compared to $7.4  million)  and related  party
service and repair fees increased by 22.9% ($966,000 compared to $786,000).

     There were  approximately  $3.4$1.4 million in foreign  revenues for the first ninethree
months of fiscal 20092010 as compared to approximately  $628,000$189,000 in foreign revenues
for the first ninethree months of fiscal 2008,2009,  representing  an increase in foreign
revenues of 434%644%. The Company is making a concerted  effort to increase  foreign
sales, most recently through its foreign distributors.

Overall,  for the first ninethree  months of fiscal  2009,2010,  revenues for the medical
equipment  segment  increased by 18.0%23.6% to $21.6$5.0 million from $18.3$4.0 million for the
first ninethree months of fiscal 2008.2009. The revenues generated by HMCA decreased,  by
15.3%8.7%,  to $7.7$2.5  million for the first ninethree months of fiscal 20092010 as compared to
$9.1$2.8 million for the first ninethree months of fiscal 2008.2009.

We recognize MRI scanner sales revenues on the "percentage of completion" basis,
which means the revenues are recognized as the scanner is manufactured. Revenues
recognized  in a  particular  quarter do not  necessarily  reflect new orders or
progress payments made by customers in that quarter. We build the scanner as the
customer meets certain  benchmarks in its site  preparation in order to minimize
the time lag between  incurring  costs of  manufacturing  and our receipt of the
cash  progress   payments  from  the  customer  which  are  due  upon  delivery.
Consequently,  there can be a disparity  between the  revenues  recognized  in a
fiscal period and the number of product sales. Generally, the recognized revenue
results from revenues from a scanner sale are  recognized in a fiscal quarter or
quarters following the quarter in which the sale was made.

Costs related to product sales increased by 48.6%14.9% from $2.2$1.4 million in the thirdfirst
quarter of fiscal 20082009 to $3.3$1.7 million in the thirdfirst quarter of 2009,2010,  reflecting
an increase in product sales  revenues.  The increase in costs by 48.6%
was  substantially  less than the  corresponding  increase in MRI product  sales
revenues of 162%, however,  primarily because we were able to both procure parts
and components at lower costs and use parts and components in inventory having a
lower cost basis.  Costs  related to providing  service  decreased by 22.1% from
$1.3 million in the third quarter of fiscal 2008 to $1.0 million in fiscal 2009.
The increase in product sales  revenues
resulted primarily from the Company'sCompanys progress in filling its backlog of orders.

Notwithstanding  the  increase in revenues  from MRI product  sales,  costsCosts related to product salesproviding  the first quarter of service  decreased by 11.4%7.0% from
$8.6$1.0 million in the first  nine
months of fiscal 2008 to $7.6  million in the first nine months of 2009  because
of our lower cost basis for parts and  components.  Costs  related to  providing
service  decreased by 21.7% from $3.9 million in the first nine months of fiscal
2008 to $3.1 million in fiscal 2009.

     Costs related to providing  service and repairs  decreased by 22.1% for the
third quarter of fiscal 2009 compared to the third quarter of$960,000 in fiscal 2008 and by
21.7% for the first nine months of fiscal 2009 compared to the first nine months
of fiscal 2008.2010. We
believe that an important factor in keeping service costs down is our ability to
monitor the  performance of customers'customers  scanners from our facilities in Melville,
New York,  on a daily basis and to detect and repair any  irregularities  before
more serious problems result.

We also believe the low cost
of providing service reflects the high quality of our products.

     Overall,  the operating results for our medical equipment segment improved to an
operating incomeloss of $207,000$902,000 for the first ninethree months of fiscal 20092010 as compared
to an operating  loss of $9.9$1.9 million for the first ninethree months of fiscal 2008.2009.
This  improvement  resulted  from an increase  in product  sales revenues and decreases in costs related to sales,  researchservice and
development and,
most significantly,  selling,  general and administrative expenses. The decrease
in costs  related  to sales  resulted  from our  ability  to  procure  parts and
components at lower costs and to use parts and components in inventory  having a
lower cost basis.  The decrease in research and  development  expenditures,  and
selling, general and administrative expenses,  resulted from our program of cost
cutting measures,  which included consolidating HMCA's office space with Fonar's
office  space,  reductions  in the  size  of  our  workforce,  compensation  and
benefits, as well as an across the board reduction of expenses.repair fees revenues.

HMCA  revenues  decreased  in the thirdfirst  quarter of fiscal  20092010 by 15.7%8.7% to $2.5
million  from $2.9  million for the third  quarter of fiscal  2008,  and by
15.3% to $7.7$2.8  million  for the first  nine monthsquarter  of fiscal  2009, from $9.1 million
for the first nine months of fiscal 2008,  primarily
because of the sale of its 92.3% interest in a previously consolidated entity in
September  2008. We now manage ten sites,  nine of which are equipped with FONAR
UPRIGHT(R) MRI scanners.  HMCA experienced an operating loss of $593,000$519,000 for the
first ninethree months of fiscal 20092010  compared to  operating  lossincome of $759,000$12,000 for
the first ninethree months of fiscal 2008.2009.

HMCA cost of revenues  decreasedincreased to $1.7  million for the third  quarter of
fiscal 2009 as compared to $2.1  million for the third  quarter of fiscal  2008.
HMCA cost of revenues for the first nine months of fiscal 2009 decreased to $5.4
million as  compared to $6.1$2.0 million for the first nine monthsquarter of fiscal
2008.2010 as  compared  to $1.9  million for the first  quarter of fiscal  2009.  The
decreaseincrease in HMCA'sHMCAs cost of revenues was primarily the result of managing one
less  scanning  center  asthe steps we have
been taking to improve HMCA  revenues by our marketing  efforts,  which focus on
the unique  capability  of our  Upright(R)  MRI  Scanners  to scan  patients  in
different positions.

In 2009, the Obama administration announced its intentions for healthcare reform
in the United States. The plan contemplates  providing  healthcare  coverage for
some 40 million  uninsured  Americans.  The plan calls for,  among other things,
more vigilant control of healthcare  utilization,  including  diagnostic imaging
services.  In  November  of 2009,  the U.S.  House of  Representatives  passed a
resulthealthcare  reform  bill.  Whether  the bill will be  approved by the Senate and
ultimately become a law is uncertain at this time.

The use of radiology benefit managers, or RBMs has increased in recent years. It
is common practice for health insurance carriers to contract with RBMs to manage
utilization of diagnostic imaging procedures for their insureds.  In many cases,
this leads to lower  utilization of imaging  procedures based on a determination
of medical necessity.  The efficacy of RBMs is still a high controversial topic.
The Company cannot predict whether the current  administrations  healthcare plan
and the use of RBMs will negatively impact its business, but it is possible that
the Companys  financial  position and results of operations  could be negatively
affected by increased utilization of RBMs.

While the  Company has  prepared  certain  estimates  of the sale of HMCA's  92.3%  interest  in a
previously consolidated entity in September, 2008.

     HMCA entered into an agreement in September, 2007 with Integrity Healthcare
Management,  Inc.  ("Integrity"),  which is a wholly-owned  subsidiary of Health
Diagnostics,  LLC.  Under the termsimpact of the agreement,  Integrity  supervisedabove
discussed  changes and directed HMCA andproposed  changes,  it is not possible to fully  quantify
their impact on its business. There can be no assurance that the managementimpact of these
changes  will not be  greater  than  estimated  or that any future  health  care
legislation  or  reimbursement  changes will not  adversely  affect the facilities  including the performance of
billing and collections services. The existing management agreements between the
facilities and HMCA remained in place. Integrity was entitled to compensation of
an annual fee equal to one-half of the increase in the consolidated cash flow of
HMCA and the facilities over the period from July 1, 2006 through June 30, 2007.
This agreement was terminated as of the end of June 2008.

     Commencing  upon  the  termination  of  this  agreement,  we  hired  Health
Diagnostics,  LLC, the parent  company of Integrity,  to perform all billing and
collection procedures for HMCA's clients on HMCA's behalf. HMCA agreed to pay 6%
of all adjusted deposits for these services. This agreement was terminated as of
April 30, 2009,  as HMCA sought to cut expenses and exercise  direct  control of
the billing and collection of its clients' accounts.Companys
business.

The  increase in our total net  revenues of 39.5%10.4% from $8.1$6.8 million in the third  quarter of fiscal  2008 to $11.3  million in the thirdfirst
quarter of fiscal 2009 to $7.5 million in the first quarter of fiscal 2010,  was
accompanied by a decreasean increase of 2.8%3.3% in total costs and expenses from $10.8$8.6 million
in the thirdfirst  quarter  of fiscal  20082009  compared  to $10.5$8.9  million  in the thirdfirst
quarter of fiscal 2009.2010.  As a result,  our income (loss)loss from  operations  changed from a
loss of $2.7  million in the third  quarter of fiscal 2008 to an
operating profit of $762,000 in the third quarter of fiscal 2009.

     For the  first  nine  months  of  fiscal  2009  the  consolidated  revenues
increased  by 7.0% to $29.3 from  $27.4  million  for the first  nine  months of
fiscal  2008  while the total  costs and  expenses  decreased  by 22.1% to $29.7
million  for the first nine  months of fiscal  2009 from $38.1  million  for the
first nine  months of fiscal  2008.  Our  operating  loss  decreased  from $10.7$1.8  million  in the first  nine  monthsquarter  of  fiscal  20082009 to $386,000a loss of $1.4
million in the first nine
monthsquarter of fiscal 2009.2010.

Selling,  general and administrative expenses decreased slightly by 36.0%1.0% to $10.0$3.2
million in the first ninethree  months of fiscal 20092010 from $15.5$3.3 million in the first
ninethree months of fiscal 2008,  largely as a result of our aggressive  cost cutting
measures.  There  was no2009. The compensatory element of stock issuances,  which
is included in selling, general and administrative expenses, inwas $18,000 for the
first ninethree  months of fiscal 2009 or 2008.2010 as compared to $0 for the first three  months
of fiscal 2009.

Research and  development  expenses  decreased by 27%3.0% to $2.7 million$854,000 for the first
ninethree  months of fiscal 20092010 as compared to $3.7  million$880,000  for the first ninethree months
of fiscal 2008.2009.

Interest  expense in the first ninethree months of fiscal 2009 decreased by 46.7%2010  increased to $193,000  from  $362,000$93,000
compared to $79,000 for the first ninethree months of fiscal 2008 because of
the repayment of existing debt.2009.

Inventories  increased by 16.5%8.8% to $3.8$3.5 million at March  31,September 30, 2009 as compared
to $3.3$3.2 million at June 30, 20082009  representing the purchase of raw materials and
components in our inventory to fill orders.

Management  fee and medical  receivables  decreased  by 20.3%3.5% to $6.1$5.6  million at
March  31,September  30,  2009  from  $7.6$5.8  million  at June 30,  2008,2009,  primarily  due to
collections on the Company'sCompanys management fee receivables and the sale of a 92.3%
interest  of a  consolidated  entity  in  September  2008,  which  included  the
receivables of such entity.medical receivables.

The overall  trends  reflected in the results of operations  for the first ninethree
months of fiscal 20092010 are an increase in revenues  from product  sales,service and repair fees,
as compared to the first ninethree months of fiscal 20082009 ($12.02.8 million for the first
ninethree  months of fiscal  20092010 as  compared  to $8.9$2.6  million for the first ninethree
months of fiscal  2008)2009),  and an  increase  in MRI  equipment  segment  revenues
relative to HMCA revenues ($21.65.0 million or 73.8%66.2% from the MRI equipment  segment
as compared to $7.7$2.5  million or 26.2%33.8% from HMCA,  for the first ninethree  months of
fiscal 2009,2010, as compared to $18.3$4.0 million or 66.8%59.2% from the MRI equipment segment
and $9.1$2.8  million or 33.2%40.8%,  from  HMCA,  for the first  ninethree  months of fiscal
2008)2009).  In
addition,  unrelatedUnrelated party sales  constituted 100% of our medical equipment product
sales for both the first ninethree months of fiscal 2009 at $12.0 million2010 and for
the first nine months of fiscal 2008 at $8.9 million.2009.

We are committed to continuingimproving the improvement in our operating  results we experienced in the first
ninethree months in fiscal 2009.2010.  Nevertheless,  factors beyond our control, such as
the  timing  and rate of market  growth  which  depend on  economic  conditions,
including the availability of credit,  payor  reimbursement  rates and policies,
and  unexpected  expenditures  or the  timing  of  such  expenditures,  make  it
impossible to forecast future operating results.  We believe we are pursuing the
correct  policies  which  should  prove  successful  in  improving  the Company'sCompanys
operating results.

Our FONAR  UPRIGHT(R)  MRI, and  Fonar-360(TM)  MRI scanners,  together with our
works-in-progress,   are  intended  to  significantly  improve  our  competitive
position.

Our FONAR UPRIGHT(R) MRI scanner,  which operates at 6000 gauss (.6 Tesla) field
strength, allows patients to be scanned while standing,  sitting,  reclining and
in multiple  flexion and extension  positions.  It is common in visualizing  the
spine that  abnormalities are visualized in some positions and not others.  This
enables surgical  corrections that heretofore would be unaddressable for lack of
visualizing the symptom causing the pathology. A floor-recessed  elevator brings
the  patient  to the  height  appropriate  for  the  targeted  image  region.  A
custom-built  adjustable  bed will allow  patients to sit or lie on their backs,
sides or  stomachs at any angle.  Full-range-of-motion  studies of the joints in
virtually any direction  are possible and another  promising  feature for sports
injuries.

Recently,  this capability of the FONAR  UPRIGHT(R)  technology has demonstrated
its key value on patients with the Arnold-Chiari syndrome,  which is believed to
affect 200,000 to 500,000  Americans.  In this syndrome,  brain stem compression
and  subsequent  severe  neurological  symptoms  occur in these  patients,  when
because of  weakness  in the support  tissues  within the skull,  the brain stem
descends and is compressed at the base of the skull in the foramen magnum, which
is the  circular  bony  opening at the base of the skull  where the spinal  cord
exits the skull.  Conventional  lie-down  MRI  scanners  cannot make an adequate
evaluation  of the pathology  since the patient's  pathology is most visible and
the   symptoms   most  acute  when  the   patient  is  scanned  in  the  upright
weight-bearing position.

The UPRIGHT(R) MRI has also  demonstrated its value for patients  suffering from
scoliosis.  Scoliosis  patients have been  typically  subjected to routine x-ray
exams for years and must be imaged  upright for an adequate  evaluation of their
scoliosis.  Because the patient must be standing for the exam,  an x-ray machine
has been the only modality that could provide that service.  The  UPRIGHT(R) MRI
is the only MRI scanner  which  allows the patient to stand during the MRI exam.
Fonar has  developed a new RF receiver and scanning  protocol that for the first
time allows  scoliosis  patients to obtain  diagnostic  pictures of their spines
without the risks of x- rays.x-rays.  A recent study by the National  'Cancer  Institute
(2000) of 5,466 women with  scoliosis  reported a 70% increase in breast  cancer
resulting from 24.7 chest x-rays these  patients  received on the average in the
course of their scoliosis treatment. The UPRIGHT(R) MRI examination of scoliosis
enables the needed imaging  evaluation of the degree of spine scoliosis  without
exposing the patient to the risk of breast  cancer from  x-radiation.  Currently
scoliosis affects more than 3,000,000 American women.

In addition,  the  University of California,  Los Angeles (UCLA)  reported their
results  of  their  study of  1,302  patients  utilizing  the  FONAR  UPRIGHT(R)
Multi-Position(TM)  MRI at the 22nd Annual  Meeting of the North  American Spine
Society on October 23, 2007.  The UCLA study showed the superior  ability of the
Dynamic(TM)   FONAR  UPRIGHT(R)  MRI  to  detect  spine   pathology,   including
spondylolisthesis,  disc  herniations  and  disc  degneration,  as  compared  to
visualizations of the spine produced by traditional single position static MRIs.

The UCLA study by MRI of 1,302 back pain patients when they were  UPRIGHT(R) and
examined in a full range of flexion and  extension  positions  made  possible by
FONAR'sFONARs  new  UPRIGHT(R)  technology   established  that  significant  "misses"misses  of
pathology were occurring with static single  position MRI imaging.  At L4-5, the
vertebral level responsible for 49.8% of lumbar disc  herniations,  35.1% of the
spondylolistheses    (vertebral   instabilities)   visualized   by   Dynamic(TM)
Multi-Position(TM)  MRI were being  missed by static  single  position  MRI (510
patients).  Since this vertebral  segment is responsible for the majority of all
disc  herniations,  the  finding may reveal a  significant  cause of failed back
surgeries.   The  UCLA  study   further   showed  the   "miss-rate"miss-rate  of  vertebral
instabilities  by static only MRI was even higher,  38.7%, at the L3-4 vertebral
segment.  Additionally  the  UCLA  study  showed  that MRI  examinations  of the
cervical  spine that did not  perform  extension  images of the neck "missed"missed disc
bulges 23.75% of the time (163 patients).

The UCLA study further  reported that they were able to  quantitatively  measure
the dimensions of the central  spinal canal with the "highest  accuracy"highest  accuracy using the
FONAR  UPRIGHT(R)  Multi-Position(TM)  MRI thereby enabling the extent of spinal
canal  stenosis that existed in patients to be measured.  Spinal canal  stenosis
gives rise to the symptom complex intermittent  neurogenic claudication manifest
as  debilitating  pain  in  the  back  and  lower   extremities,   weakness  and
difficulties  in ambulation  and leg  paresthesias.  Spinal canal  stenosis is a
spinal  compression  syndrome  separate and distinct  from the more common nerve
compression  syndrome  of the spinal  nerves as they exit the  vertebral  column
through the bony neural foramen.

The  FONAR  UPRIGHT(R)  MRI  can  also be  useful  for  MRI  directed  emergency
neuro-surgical  procedures  as the surgeon would have  unhindered  access to the
patient'spatients  head when the patient is supine with no  restrictions  in the vertical
direction.  This  easy-entry,  mid-field-strength  scanner could prove ideal for
trauma  centers where a quick  MRI-screening  within the first  critical hour of
treatment will greatly  improve  patients'patients  chances for survival and optimize the
extent of recovery.

The Fonar 360(TM) is an enlarged  room sized magnet in which the floor,  ceiling
and walls of the scan room are part of the magnet  frame.  This is made possible
by Fonar'sFonars patented Iron-Frame(TM) technology which allows the Company'sCompanys engineers
to  control,  contour  and direct the  magnet'smagnets  lines of flux in the patient gap
where  wanted and  almost  none  outside  of the steel of the  magnet  where not
wanted.  Consequently,  this scanner  allows  surgeons and other  interventional
physicians  to walk  inside  the  magnet and  achieve  360 degree  access to the
patient to perform interventional procedures.

The Fonar 360(TM) is presently marketed as a diagnostic scanner and is sometimes
referred to as the Open  Sky(TM)  MRI. In its Open  Sky(TM)  version,  the Fonar
360(TM)  serves as an open  patient  friendly  scanner  which  allows 360 degree
surgical   access  to  the  patient  on  the  scanner   bed.  To  optimize   the
patient-friendly  character of the Open Sky(TM) MRI, the walls,  floor,  ceiling
and magnet poles are decorated with landscape murals.  The patient gap is twenty
inches and the magnetic field strength,  like that of the FONAR  UPRIGHT(R),  is
0.6 Tesla.

In the future, we expect the Fonar 360(TM) to function as an interventional MRI.
The  enlarged  room sized  magnet and 360o360 access to the patient  afforded by the
Fonar  360(TM)  permits  surgeons to walk into the magnet and  perform  surgical
interventions  on the patient under direct MR image guidance.  Most  importantly
the  exceptional  quality of the MRI image and its  capacity  to exhibit  tissue
detail on the image,  can then be  obtained  real time during the  procedure  to
guide the  interventionalist.  Thus surgical  instruments,  needles,  catheters,
endoscopes  and the like could be  introduced  directly  into the human body and
guided  directly  to a  malignant  lesion  using the MRI  image.  The  number of
inoperable  lesions could be  significantly  reduced by the availability of this
new FONAR technology.  Most importantly treatment can be carried directly to the
target tissue.

The first Fonar 360(TM) MRI scanner, installed at the Oxford-  NuffieldOxford-Nuffield Orthopedic
Center in Oxford,  United  Kingdom,  is now carrying a full  diagnostic  imaging
caseload.  In  addition,  however,  development  of the works in progress  Fonar
360(TM) MRI image  guided  interventional  technology  is actively  progressing.
Fonar  software  engineers  have  completed and installed  their 2nd  generation
tracking software at Oxford-Nuffield which is designed to enable the surgeons to
insert needles into the patient and accurately advance them, under direct visual
image  guidance,  to the target  tissue,  such as a tumor,  so that  therapeutic
agents can be injected.

The Company  expects  marked demand for its most  commanding  MRI products,  the
FONAR UPRIGHT(R) MRI and the Fonar 360(TM) because of their exceptional features
in patient diagnosis and treatment. These scanners additionally provide improved
image quality and higher imaging speed because of their higher field strength of
..60.6 Tesla.  The  geometry  of the FONAR  UPRIGHT(R)  MRI as compared to a single
coil,  or  multiple  coils on only one axis and its  transverse  magnetic  field
enables the use of two detector rf coils operating in quadrature which increases
the FONAR  UPRIGHT(R)  MRI signal to noise  ratio by 40%,  providing a signal to
noise ratio equal to a .84T recumbent only MRI scanner.

Liquidity and Capital Resources

Cash, cash equivalents and marketable  securities decreasedincreased from $2.4$1.2 million at
June 30, 20082009 to $1.6$1.4  million at  March  31,September  30,  2009.  Marketable  securities
approximated  $18,000$27,000 as of March 31,September  30, 2009,  as compared to $1.1
million$23,000 at June
30, 2008.2009.

Cash used in operating  activities for the first ninethree months of fiscal 20092010 was
$5.7  million.$402,000.  Cash used in operating  activities was attributable to a
decreasean increase in
customer advancesaccounts  payable of  $5.6 million,  a decrease$269,000,  an  increase in billings in excess of costs and
estimated earnings on uncompleted  contracts of $641,000$509,000 and a decrease in costs
and  estimated  earnings  in excess of  billings  on  uncompleted  contracts  of
$264,000  offset by an increase in  accounts,  management  fee and medical  receivablesinventories  of $1.1 million
offset by a decrease in notes  receivable of $385,000$280,000 and the net incomeloss of
$1.1$1.7 million.

Cash provided byused in investing  activities for the first ninethree months of fiscal 20092010 was
$6.1
 million.$200,000.  The principal  source of cash from  investing  activities  during the
first ninethree months of fiscal 2009 consisted  mainly of proceeds from the sale
of a consolidated subsidiary of $2.3 million,  proceeds of $2.0 million from the
prepayment by a debtor of a portion of a note  receivable and sale of marketable
securities of $1.1 million,  offset by capitalized  software and
patent costs of $584,000.$193,000.

Cash used in financing  activities for the first ninethree months of fiscal 20092010 was
$141,000.$56,000.  The principal  uses of cash in financing  activities  during the first
ninethree  months of fiscal 20092010  consisted  of  repayment of principal on long-
termlong-term
debt and capital lease obligations of $243,000,$57,000, and repayment of notes receivable
from employee stockholders of $125,000 and  distributions to holders
of minority interests of $23,000.$1,000.

The  Company's  contractual  obligations  and the  periods  in  which  they  are
scheduled to become due are set forth in the following table:


                                 (000s OMITTED)

                               Due in
                               less        Due         Due         Due
Contractual                    Than 1      in 2-3      in 4-5     after 5
Obligation         Total       year        years       years       years
- --------------   -----------   ----------   ----------   ----------   -------------------   ---------   ---------   ---------   ---------

Long-term debt   $    545928    $    22221    $    --175    $   ---       $    523532

Capital lease
  Obligations         342            119         223          --             --291         128         163        -           -

Operating
  leases           11,512          1,731       3,732        3,517         2,532
                 -----------   ----------     --------Leases           11,529       2,011       4,081       3,446       1,991

Stipulation
  Agreements          588         432         156
                 ---------   -------------------   ---------   ---------   ---------
Total cash
  Obligations    $ 12,39913,336    $  1,8722,792    $  3,9554,575    $  3,5173,446    $  3,055
                 ==========    ==========     ========2,523
                 =========   ===================   =========   =========   =========

Total liabilities  decreasedincreased by 17.1%2.6% to $32.6$32.0 million at March 31,September 30, 2009 from
$39.3$31.2 million at June 30, 2008.2009. We experienced an decrease in long-term debt and
capital  leases from $757,000$759,000 at June 30, 20082009 to $746,000$731,000 at March 31,September 30, 2009
and a decreasean increase in accounts  payable  from $4.0$3.7 million at June 30, 20082009 to $3.7$4.0
million at March 31,September  30, 2009,  along with a decreasean increase in billings in excess of
costs and estimated earnings on uncompleted  contracts from $5.8$2.0 million at June
30, 20082009 to $5.1$2.5  million at  March 31,September  30,  2009,  and a decreasean increase in customer
advances  from $14.3$9.2 million at June 30, 20082009 to $8.7$9.3  million at  March 31,September  30,
2009.  Unearned revenue on service contracts increased from $5.2$5.5 million at June
30, 20082009 to $5.7$5.6 million at March 31,September 30, 2009.

As of March  31,September 30, 2009, the total of $8.0$8.4 million in other current liabilities
included  primarily accrued salaries and payroll taxes of $1.1 million,  accrued
interest of $792,000,  accrued royalties of $623,000 and excise$947,000 and sales taxes of $2.7$2.5 million.

Our working  capital deficit  decreased  from $16.0remained  constant at $10.8 million as of June 30,
2008 to $12.5  million as of March 31,2009 and  September 30, 2009.  This resulted from decreasean increase in current  assets
($18.3  million at June 30, 2009 as compared to $19.2  million at September  30,
2009)  particularly  an increase in the current  portion of notes  receivable of
$1.1 million ($518,000 at June 30, 2009 as compared to $1.7 million at September
30, 2009),  notwithstanding an increase in current liabilities ($38.029.1 million at
June 30, 20082009 as compared to $31.4$30.0  million at  March 31, 2009,  particularly a decreaseSeptember  30,  2009)  resulting
primarily from an increase of  approximately  $297,000 in customer advancesthe current portion of
$5.6 millionaccounts  payable  ($14.33.5 million at June 30, 20082009 as compared to $8.7$3.8 million at
March 31,September  30,  2009), and a  decreasean increase of $510,000 in billings in excess of costs
and estimated  earnings on uncompleted  contracts from $5.8($2.0 million at June 30, 2008 to $5.1  million at
March 31, 2009;  notwithstanding  a decrease in current assets ($22.0 million at
June 30, 2008 compared to $19.0 million at March 31, 2009)  resulting  primarily
from a decrease in management  fee  receivable of $881,000 ($6.4 million at June
30, 2008  compared to $5.5  million at March 31, 2009) and a decrease in current
portion of notes  receivable  ($2.5  million  at June 30,  20082009
as compared to $509,000 at March 31,  2009),  offset by an increase in accounts  receivable  of
$667,000 ($5.2$2.5 million at JuneSeptember 30, 2008 as compared to $5.8 million at March 31,
2009) and an increase in inventories of approximately  $537,000 ($3.3 million at
June 30, 2008 as compared to $3.8 million at March 31, 2009).

Fonar has not committed to making additionalany  significant  capital  expenditures in the
20092010 fiscal year.

Our business  plan calls for a continuing  emphasis on providing  our  customers
with enhanced  equipment  service and  maintenance  capabilities  and delivering
state-of-the-art,  innovative and high quality equipment upgrades at competitive
prices.

Our principal  source of liquidity has been derived from revenues,  as well
as by the sale of marketable  securities and cash provided by notes  receivable.
Also, in September  2008,  the Company sold its 92.3% interest in a consolidated
subsidiary and to a related third party and received  proceeds of  approximately
$2.3 million. In addition,  during the third quarter of fiscal 2009, the Company
received  $1.3 million from loans it made against the cash value of certain life
insurance policies. At March 31, 2009, we had a working capital deficit of $12.5
million.  For the nine months ended March 31, 2009,  we had a net income of $1.1
million which included non-cash charges of $2.4 million.

     The Company is focusingcontinues to focus its efforts on increased  marketing  campaigns and distribution
programs to
increasestrengthen the demand for Fonar's  products.its products and services. Management anticipates that
Fonar'sits capital  resources  will improve as Fonar'sif Fonars MRI scanner  products  gain wider
market recognition and acceptance  resulting in increased product sales. If
we are not successful with our current marketing efforts to increase sales, then
we could  experience a shortfall in the cash necessary to sustain  operations at
their current levels.

     Although  sales levels  remained weak in fiscal 2009,  the Company has been
profitable for two consecutive  quarters; we are continuing to focus our efforts
on  increased  marketing   campaigns,   in  particular,   by  expanding  Fonar's
utilization of internet  advertising as a vehicle for promoting our products and
their unique  features to the medical  community and displaying the high quality
visualization they achieve of pathologies that can not be seen by recumbent only
MRI  technology.  Management  anticipates  that Fonar's  capital  resources will
improve if Fonar's  MRI  scanner  products  gain wider  market  recognition  and
acceptance  resulting in increased  product sales. If we are not successful with
our  marketing  efforts to  increase  sales and weak demand  continues,  we will
experience a shortfall in cash over the next twelve  months.  If necessary,  the
Company will  implement its plan to fund such a deficit which  includes  further
reductions in operating expenses, sales of certain assets and loans from related
parties together in an amount  sufficient to continue as a going concern through
March 31, 2010. Current
economic credit  conditions have contributed to a slowing business  environment.
Given such liquidity and credit constraints in the markets, the business has and
may  continue  to  suffer,  should the credit  markets  not  improve in the near
future. The direct impact of these conditions is not fully known. However, there
can be no assurance that wethe Company would be able to secure additional funds if
needed and that if such funds were  available,  whether the terms or  conditions
would be  acceptable  to us.

     NASDAQthe  Company.  In such case,  the further  reduction in
operating  expenses as well as  possible  sale of other  operating  subsidiaries
might need to be substantial in order for the Company to generate  positive cash
flow to sustain the operations of the Company.

At  September  30,  2009,  the  Company  had granteda  working  capital  deficiency  of
approximately $10.8 million and a stockholders  deficiency of approximately $4.7
million.  For the three months ended September 30, 2009, the Company  incurred a
net loss of  approximately  $1.7 million,  which  included  non-cash  charges of
approximately  $914,000.  The Company  has funded its cash flow  deficit for the
three months ended September 30, 2009 through cash provided by operations.

On October 27, 2009,  subsequent to the end of the first fiscal quarter of 2010,
to improve our  liquidity  the Company  entered into an agreement  with Mountain
Crest  Ventures  LLC to  assign  the  promissory  note  issued  by  Health  Plus
Management  Services,  LLC in connection  with a Asset Purchase  Agreement which
closed in July, 2005. The Company  received  $1,580,862,  which  represented the
remaining principal balance less a discount of $350,000. Mountain Crest Ventures
LLC  retains  all rights  under the  original  promissory  note to  collect  all
remaining  payments  due.  The Company  recorded  the  $350,000  discount in the
financial statements for the three months ended September 30, 2009.

Management  anticipates that Fonars capital resources will improve if (1) Fonars
MRI scanner products gain wider market  recognition and acceptance  resulting in
increased  product sales, (2) service and maintenance  revenues  increase as the
warranties on scanners expire and (3) HMCA revenues can be increased through the
Companys vigorous  marketing efforts.  In addition,  Management is exploring the
possibility of equity and/or loan financing to improve liquidity.  If we are not
successful  with our  marketing  efforts to increase  revenues and are unable to
raise debt or equity  capital,  we will  experience a shortfall in cash,  and it
will be necessary to further reduce  operating  expenses to attempt to avoid the
need  to  curtail  our  operations.  Current  economic  credit  conditions  have
contributed  to a slowing  business  environment.  The  precise  impact of these
conditions can not be fully  predicted.  There can be no assurance that we would
be able to secure additional funds if needed.

The  accompanying  financial  statements  have been prepared in accordance  with
accounting  principals  generally  accepted in the United  States of America and
assume  that the  Company  will  continue  as a going  concern.  The Company has
suffered  recurring losses from operations,  continues to generate negative cash
flows from operating  activities and had negative  working  capital at September
30, 2009. These conditions raise substantial doubt about the Companys ability to
continue  as a going  concern.  The  accompanying  financial  statements  do not
include any adjustments that might result from the outcome of this uncertainty.

Fonar an  extensionwas able to April  9,  2009 to  evidence
compliance  with the minimum  stockholders'  equity  requirement  formaintain its continued listing on the NASDAQ Capital Market.  Although  Fonar was unable to raise the
equity financing necessary to do so, Fonar's common stock continues to be listed
pending its appeal to the NASDAQ  Listing and Hearing Review  Council.  Fonar is
requesting an extension  until after the filing of its form 10-KMarket by
demonstrating  a net income for fiscal 2009 to  demonstrate   compliance   with  one  or  morein the amount of $1.1 million,  well
in excess of the minimum continued listing requirements.


                       FONAR CORPORATION AND SUBSIDIARIESrequirement of $500,000.


Item 3. Quantitative and Qualitative Disclosures About Market Risk

The Company maintains its funds in liquid accounts.  None of our investments are
in fixed rate instruments.

All of our revenue,  expense and capital purchasing activities are transacted in
United States dollars.

Item 4.4T. Controls and Procedures

(a)  Evaluation of disclosureDisclosure Controls and Procedures

Disclosure controls and procedures.

     The  Company  maintainsprocedures (as defined in Rule 13(a)-15(e)) are controls
and other procedures that are designed to ensure that information required to be
disclosed by a public  company in the reports that it files or submits under the
Securities Exchange Act, of 1934 is recorded,  processed,  summarized and reported  within the time
periods  specified  in  the  SECs  rules  and  forms of the
Securities  and  Exchange  Commission.  Based  upon  their  evaluation  of thoseforms.  Disclosure  controls  and
procedures  performed as ofinclude,  without  limitation,  controls and procedures  designed to
ensure that  information  required to be  disclosed  by a public  company in the
end ofreports  that it files or submits  under the  period  covered by this
report,Exchange  Act is  accumulated  and
communicated to the companys  management,  including its principal executive and
acting principal  financial  officerofficers,  or persons  performing  similar  functions,  as
appropriate  to  allow  for  timely  decisions  regarding  required  disclosure.
Disclosure controls and procedures include many aspects of internal control over
financial reporting.

In connection with the Company concluded thatpreparation of this Quarterly Report on Form 10-Q for the
quarter ended  September 30, 2009,  management,  with the  participation  of our
Chief  Executive  Officer  and  Chief  Financial  Officer,   has  evaluated  the
effectiveness of our disclosure  controls and procedures pursuant to Rule 13a-15
under the Exchange Act and have  determined  that such  controls and  procedures
were effective.

(b)  Changeeffective as of September 30, 2009.

Changes in internal controls.Internal Control Over Financial Reporting

There have beenwere no changes in our  internal  control over financial reportingcontrols or in other  factors that occurredcould
significantly  affect these  controls,  during the most  recent  fiscal  quarter  ended  September 30,
2009,  that have  materially  affected,  or are reasonably  likely to materially
affect, our internal control over financial reporting.



                       FONAR CORPORATION AND SUBSIDIARIES

PART II - OTHER INFORMATION

Item 1 - Legal  Proceedings:There  were no material  changes in litigation for the
     first ninethree months of fiscal 2009.2010.

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds: None

Item 3 - Defaults Upon Senior Securities: None

Item 4 - Submission of Matters to a Vote of Security Holders: None

Item 5 - Other Information: None

Item 6 - Exhibits and Reports on Form 8-K:  Exhibits Exhibit 31.1  Certification
     See Exhibits  Exhibit 32.1  Certification  See Exhibits  Report on Form 8-K
     containing the Companys Earnings Report for fiscal 2009. See Report on Form
     8-K dated October 5, 2009, Commission File No. 000-10248


                       FONAR CORPORATION AND SUBSIDIARIES


SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

FONAR CORPORATION
(Registrant)

By: /s/Raymond V. Damadian
    ----------------------
       Raymond V. Damadian
       President & Chairman

Dated:May 18, November 23, 2009